An Open-Label, Multicenter, Rollover Study to Evaluate the Safety and Tolerability of Long-Term Administration of Gantenerumab in Participants With Alzheimer's Disease
Phase: PHASE3
Conditions: Alzheimer Disease
Sponsor: Hoffmann-La Roche



Gantenerumab —F. Hoffmann-La Roche Ltd
2/Protocol WN41874, Version 2
PROTOCOL HISTORY
Protocol
Version
Date Final
2
See electronic date stamp on title page
1
27 November 2019

Gantenerumab —F. Hoffmann-La Roche Ltd
3/Protocol WN41874, Version 2
PROTOCOL AMENDMENT, VERSION 2:
RATIONALE
Protocol WN41874 has been amended to allow participants who complete dosing visit 
(Week 104) to continue participation in the study for an additional 2 years.  Changes to 
the protocol, along with a rationale for each change, are summarized below:

The study has been accordingly divided in to two parts. Part 1 reflects the initial
study period of 2 years and Part 2 reflects the study period of additional 2 years
beyond the initial 2 years because the safety profile combined with the potential
benefit indicates that a longer period of treatment is justified. The protocol body has
been updated accordingly to clarify Part 1 from Part 2. Text from Part 1 has also
been updated from present to past tense to reflect the completion of Part 1, where
applicable.

To reflect the recent study status in alignment with the Gantenerumab
Investigator’s Brochure v17, Sections 1.2.1, 1.2.1.4 and 1.2.2 have been updated
accordingly.

Benefit-risk assessment on concomitant administration of severe acute respiratory
syndrome coronavirus 2 vaccines with gantenerumab has been added to address a
Health Authority request. Section 1.3.3 has been updated accordingly.

The sample size for Part 1 of the study was not available at the time of writing the
protocol, as it was going to be determined by the number of participants who
complete OLE part of Studies WN25203 and WN28745. As this number has now
been determined. Section 3 has been updated accordingly.

Sections 4.4.1 have been revised to clarify the Medical Monitor’s responsibility to
review and support participant cohort management and other protocol activities.
Any reference to approval by the Medical Monitor with regards to medical decisions
following enrollment has been removed from the protocol.  This means that the
Principal Investigator (PI) may consult with the Medical Monitor/Sponsor for advice
or clarification and may share risk factor information pertinent to the participant, but
the medical decisions for the study participants are the responsibility of the PI.

Section 4.1.1 (Inclusion Criteria) has been updated to:
–
Include the requirement to agree not to donate blood or blood products during
the study and for one year after final dose
–
Include the requirement for a caregiver during the study.

Language has been added to clarify that adverse events associated with a special
situation that also qualify as adverse events of special interest should be reported
within 24 hours. Section 5.3.5.13 has been updated accordingly.

Language has been added to indicate that the Informed Consent Form will instruct
female participants to inform the investigator if they become pregnant. Section
5.4.3.1 has been updated accordingly.

The name of a Roche policy on data sharing has been corrected. Section 9.6 has
been updated accordingly.

Gantenerumab —F. Hoffmann-La Roche Ltd
4/Protocol WN41874, Version 2
Additional minor changes have been made to improve clarity and consistency.  
Substantive new information appears in italics.  This amendment represents cumulative 
changes to the original protocol.

Gantenerumab —F. Hoffmann-La Roche Ltd
5/Protocol WN41874, Version 2
TABLE OF CONTENTS
PROTOCOL ACCEPTANCE FORM .................................................................. 11
PROTOCOL SYNOPSIS .................................................................................... 12
1.
BACKGROUND .......................................................................................... 18
1.1
Background on Alzheimer’s Disease..................................... 18
1.2
Background on Gantenerumab.............................................. 18
1.2.1
Clinical Studies...................................................................... 19
1.2.1.1
Study NN19866 ..................................................................... 20
1.2.1.2
Study WN25203 .................................................................... 20
1.2.1.3
Study WN28745 .................................................................... 21
1.2.1.4
OLE Studies WN25203 and WN28745.................................. 21
1.2.2
Safety Overview .................................................................... 22
1.3
Study Rationale and BenefitRisk Assessment..................... 24
1.3.1
Study Rationale ..................................................................... 25
1.3.2
Rationale for Dosing Strategy................................................ 25
1.3.3
Overall BenefitRisk Summary.............................................. 25
2.
OBJECTIVES AND ENDPOINTS ............................................................... 26
3.
STUDY DESIGN......................................................................................... 27
3.1
Description of the Study......................................................... 27
3.1.1
Overview of Study Design in Part 1 ...................................... 27
3.1.2
Overview of the Study Design in Part 2 ............................... 28
3.1.3
Internal Monitoring Committee............................................... 29
3.2
End of Study and Length of Study......................................... 29
3.3
Rationale for Study Design.................................................... 29
3.3.1
Rationale for Gantenerumab Dose and Schedule
Part 1..................................................................................... 29
3.3.2
Rationale for Participant Population..................................... 29
3.3.3
Rationale for Key Endpoints (Part 1 and Part 2)................... 30
3.3.4
Rationale for Study Treatment Duration ................................ 30
3.3.5
Rationale for Biomarker Assessments................................... 30
3.3.5.1
Blood Biomarkers .................................................................. 30

Gantenerumab —F. Hoffmann-La Roche Ltd
6/Protocol WN41874, Version 2
3.3.5.2
Brain Volumetry..................................................................... 30
4.
MATERIALS AND METHODS .................................................................... 31
4.1
Participants .......................................................................... 31
4.1.1
Inclusion Criteria.................................................................... 31
4.1.2
Exclusion Criteria................................................................... 32
4.1.3
Eligibility in Part 2 ............................................................... 32
4.2
Method of Treatment Assignment and Blinding..................... 32
4.3
Study Treatment and Other Treatments Relevant 
to the Study Design ............................................................... 33
4.3.1
Formulation, Packaging, and Handling.................................. 33
4.3.1.1
Non-Investigational Medicinal Products................................. 33
4.3.1.2
Compliance............................................................................ 34
4.3.2
Investigational Medicinal Product Accountability ................... 34
4.3.3
Continued Access to Gantenerumab..................................... 35
4.4
Concomitant Therapy ............................................................ 35
4.4.1
Permitted and Prohibited Therapy......................................... 36
4.5
Study Assessments ............................................................... 36
4.5.1
Informed Consent Forms and Screening Log........................ 36
4.5.2
Medical History, Baseline Conditions, 
Concomitant Medication, and Demographic Data ................. 37
4.5.3
Physical Examinations........................................................... 37
4.5.4
Vital Signs.............................................................................. 38
4.5.5
Cognitive Assessments ......................................................... 38
4.5.6
Laboratory Assessments ....................................................... 38
4.5.7
Electrocardiograms................................................................ 40
4.5.8
Columbia-Suicide Severity Rating Scale ............................... 40
4.5.9
Brain Magnetic Resonance Imaging...................................... 41
4.5.9.1
Healthy Volunteer Magnetic Resonance Imaging 
Scans for Site Qualification.................................................... 42
4.5.10
Optional Samples for Research Biosample 
Repository ............................................................................. 42
4.5.10.1
Overview of the Research Biosample Repository.................. 42
4.5.10.2
Approval by the Institutional Review Board or 
Ethics Committee .................................................................. 43

Gantenerumab —F. Hoffmann-La Roche Ltd
7/Protocol WN41874, Version 2
4.5.10.3
Sample Collection.................................................................. 43
4.5.10.4
Confidentiality........................................................................ 43
4.5.10.5
Consent to Participate in the Research 
Biosample Repository............................................................ 44
4.5.10.6
Withdrawal from the Research Biosample 
Repository ............................................................................. 44
4.5.10.7
Monitoring and Oversight....................................................... 44
4.5.11
Unscheduled Assessments ................................................... 45
4.6
Treatment, Participant, Study, and Site 
Discontinuation...................................................................... 45
4.6.1
Study Treatment Discontinuation........................................... 45
4.6.2
Participant Discontinuation................................................... 45
4.6.3
Study Discontinuation............................................................ 46
4.6.4
Site Discontinuation............................................................... 46
5.
ASSESSMENT OF SAFETY....................................................................... 46
5.1
Safety Plan ............................................................................ 46
5.1.1
Risks Associated with Gantenerumab ................................... 47
5.1.1.1
Amyloid-Related Imaging Abnormalities................................ 47
5.1.1.2
Injection-Site Reactions......................................................... 48
5.1.1.3
Immunogenicity ..................................................................... 48
5.1.2
Management of Participants Who Experience 
Selected Adverse Events....................................................... 49
5.2
Safety Parameters and Definitions ........................................ 49
5.2.1
Adverse Events ..................................................................... 49
5.2.2
Serious Adverse Events (Immediately Reportable 
to the Sponsor)...................................................................... 50
5.2.3
Adverse Events of Special Interest (Immediately 
Reportable to the Sponsor).................................................... 51
5.2.4
Selected Adverse Events....................................................... 51
5.3
Methods and Timing for Capturing and 
Assessing Safety Parameters................................................ 51
5.3.1
Adverse Event Reporting Period ........................................... 51
5.3.2
Eliciting Adverse Event Information....................................... 52
5.3.3
Assessment of Severity of Adverse Events ........................... 52
5.3.4
Assessment of Causality of Adverse Events ......................... 52

Gantenerumab —F. Hoffmann-La Roche Ltd
8/Protocol WN41874, Version 2
5.3.5
Procedures for Recording Adverse Events............................ 53
5.3.5.1
Amyloid-related Imaging Abnormality Findings...................... 53
5.3.5.2
Injection Reactions ................................................................ 53
5.3.5.3
Diagnosis vs. Signs and Symptoms ...................................... 53
5.3.5.4
Adverse Events That Are Secondary to Other 
Events.................................................................................... 54
5.3.5.5
Persistent or Recurrent Adverse Events................................ 54
5.3.5.6
Abnormal Laboratory Values ................................................. 55
5.3.5.7
Abnormal Vital Sign Values ................................................... 55
5.3.5.8
Abnormal Liver Function Tests.............................................. 56
5.3.5.9
Deaths ................................................................................... 56
5.3.5.10
Preexisting Medical Conditions.............................................. 57
5.3.5.11
Lack of Efficacy or Worsening of 
Alzheimer’s Disease .............................................................. 57
5.3.5.12
Hospitalization or Prolonged Hospitalization.......................... 57
5.3.5.13
Cases of Accidental Overdose or Medication 
Error....................................................................................... 58
5.4
Immediate Reporting Requirements from 
Investigator to Sponsor.......................................................... 59
5.4.1
Emergency Medical Contacts................................................ 59
5.4.2
Reporting Requirements for Serious Adverse 
Events and Adverse Events of Special Interest..................... 60
5.4.2.1
Events That Occur prior to Study Drug Initiation.................... 60
5.4.2.2
Events That Occur after Study Drug Initiation........................ 60
5.4.3
Reporting Requirements for Pregnancies.............................. 60
5.4.3.1
Pregnancies in Female Participants ..................................... 60
5.4.3.2
Abortions ............................................................................... 61
5.4.3.3
Congenital Anomalies/Birth Defects ...................................... 61
5.4.4
Reporting Requirements for Medical Device 
Complaints............................................................................. 61
5.5
Follow-Up of Participants after Adverse Events.................... 62
5.5.1
Investigator Follow-Up........................................................... 62
5.5.2
Sponsor Follow-Up ................................................................ 62
5.6
Adverse Events That Occur after the Adverse 
Event Reporting Period.......................................................... 62

Gantenerumab —F. Hoffmann-La Roche Ltd
9/Protocol WN41874, Version 2
5.7
Expedited Reporting to Health Authorities, 
Investigators, Institutional Review Boards, and 
Ethics Committees................................................................. 62
6.
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN....................... 63
6.1
Determination of Sample Size ............................................... 63
6.2
Summaries of Conduct of Study............................................ 63
6.3
Summaries of Demographic and Baseline 
Characteristics....................................................................... 63
6.4
Efficacy Analyses .................................................................. 64
6.4.1
Exploratory Efficacy Endpoints.............................................. 64
6.4.2
Secondary Efficacy Endpoints............................................... 64
6.5
Safety Analyses..................................................................... 64
6.6
Pharmacokinetic Analyses..................................................... 64
6.7
Biomarker Analyses............................................................... 64
6.8
Interim Analysis ..................................................................... 64
7.
DATA COLLECTION AND MANAGEMENT ............................................... 65
7.1
Data Quality Assurance......................................................... 65
7.2
Electronic Case Report Forms............................................... 65
7.3
Electronic Data ...................................................................... 65
7.4
Source Data Documentation.................................................. 65
7.5
Use of Computerized Systems .............................................. 66
7.6
Retention of Records............................................................. 66
8.
ETHICAL CONSIDERATIONS.................................................................... 67
8.1
Compliance with Laws and Regulations ................................ 67
8.2
Informed Consent.................................................................. 67
8.3
Institutional Review Board or Ethics Committee.................... 68
8.4
Confidentiality........................................................................ 68
8.5
Financial Disclosure .............................................................. 69
9.
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION ..................................................................................... 69
9.1
Study Documentation ............................................................ 69
9.2
Protocol Deviations................................................................ 70
9.3
Management of Study Quality ............................................... 70

Gantenerumab —F. Hoffmann-La Roche Ltd
10/Protocol WN41874, Version 2
9.4
Site Inspections ..................................................................... 70
9.5
Administrative Structure......................................................... 70
9.6
Dissemination of Data and Protection of 
Trade Secrets........................................................................ 71
9.7
Protocol Amendments ........................................................... 72
10. REFERENCES ........................................................................................... 73
LIST OF TABLES
Table 1
Objectives and Corresponding Endpoints................................... 26
Table 2
Adverse Event Severity Grading Scale ....................................... 52
LIST OF APPENDICES
Appendix 1
Schedule of Activities (Part 1 and Part 2) .................................. 75
Appendix 2
Management Rules for Amyloid-Related Imaging 
Abnormalities .............................................................................. 79
Appendix 3
Gantenerumab Dosing Schedule for the Study (only for Part 
1) ................................................................................................ 81

Gantenerumab —F. Hoffmann-La Roche Ltd
11/Protocol WN41874, Version 2
PROTOCOL ACCEPTANCE FORM
TITLE:
AN OPEN-LABEL, MULTICENTER, ROLLOVER 
STUDY TO EVALUATE THE SAFETY AND 
TOLERABILITY OF LONG-TERM ADMINISTRATION
OF GANTENERUMAB IN PARTICIPANTS WITH 
ALZHEIMER’S DISEASE
PROTOCOL NUMBER:
WN41874
VERSION NUMBER:
2
EUDRACT NUMBER:
2019-004431-23
IND NUMBER:
102,266
NCT NUMBER
NCT04339413
TEST PRODUCT:
Gantenerumab (RO4909832)
MEDICAL MONITOR:
, M.D.
SPONSOR:
F. Hoffmann-La Roche Ltd
I agree to conduct the study in accordance with the current protocol.
Principal Investigator's Name (print)
Principal Investigator's Signature
Date
Please retain the signed original of this form for your study files.  Please return a copy of 
the signed form as instructed by your local study monitor to the contact provided below.
Name 
Address

Gantenerumab —F. Hoffmann-La Roche Ltd
12/Protocol WN41874, Version 2
PROTOCOL SYNOPSIS
TITLE:
AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO 
EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM 
ADMINISTRATION OF GANTENERUMAB IN PARTICIPANTS 
WITH ALZHEIMER’S DISEASE
PROTOCOL NUMBER:
WN41874
VERSION NUMBER:
2
EUDRACT NUMBER:
2019-004431-23
IND NUMBER:
102,266
TEST PRODUCT:
Gantenerumab (RO4909832)
PHASE:
III
INDICATION:
Alzheimer’s disease
SPONSOR:
F. Hoffmann-La Roche Ltd
Objectives and Endpoints
The main objective of this study (Part 1 and Part 2) is to continue to collect long-term safety 
and tolerability data in participants with Alzheimer's disease (AD) treated with gantenerumab.  
Specific objectives and corresponding endpoints for the study are outlined below.

Gantenerumab —F. Hoffmann-La Roche Ltd
13/Protocol WN41874, Version 2
Objectives and Corresponding Endpoints
Safety Objective
Corresponding Endpoints
To evaluate the long-term safety and 
tolerability of continued treatment with 
SC gantenerumab at target dose in 
participants with AD who received 
gantenerumab in OLEs of 
Studies WN25203 or WN28745
Nature, frequency, severity, and timing of AEs and 
SAEs
Physical examinations (including neurological 
systems), vital signs, blood tests, ECGs, and 
C-SSRS
Nature, frequency, severity, and timing of MRI 
findings:  ARIA-E and ARIA-H
Nature, frequency, severity, and timing of 
injection-site reactions
Immunogenicity of long-term treatment with 
gantenerumab through the measurements of ADAs 
Incidence of treatment discontinuations for AEs
Incidence of AEs of special interest
Exploratory Efficacy Objective
Corresponding Endpoint
To assess the long-term clinical effect 
in participants with AD
MMSE total score will be used to assess AD 
progression
Exploratory Pharmacodynamic 
Biomarker Objective
Corresponding Endpoints
To evaluate the long-term effect of 
gantenerumab in participants with AD
MRI-derived measurements over time, such as 
volumetric changes in whole brain, ventricles, 
hippocampus, or other structures, in all participants
Plasma pharmacodynamic biomarkers over time
ADAlzheimer's disease; ADAanti-drug antibody; AEadverse event; 
ARIA-Eamyloid-related imaging abnormalitiesedema/effusion; ARIA-Hamyloid-related 
imaging abnormalities hemosiderin deposition; C-SSRSColumbia-Suicide Severity Rating 
Scale; ECGelectrocardiogram; MMSEMini Mental State Examination; MRImagnetic 
resonance imaging; OLEopen-label extension; SAE serious adverse event; 
SCsubcutaneous.
Study Design
Description of Study
All participants who had completed the open-label extension (OLE) of Studies WN25203 or
WN28745 (i.e., not discontinued from study drug) were eligible for this study.  
Participants will receive open-label gantenerumab by subcutaneous (SC) injection every 
4 weeks (Q4W) for up to an additional 2 years beyond the initial 2 years of the OLE, followed 
by a safety and Mini Mental State Examination (MMSE) assessment 4 weeks following the last 
dose (follow-up visit; see Schedule of Activities).  The first dose of open-label gantenerumab will 
be administered after the participant has signed the Informed Consent Form for this study.  
Participants who discontinue study drug at any time during this study will be asked to complete 
follow-up visits at 4 weeks from their last dose.
Target Population
Inclusion Criteria
All participants who completed the OLEs of Studies WN25203 or WN28745 (i.e., latest version 
of protocol in their countries, and did not discontinue study drug early) were eligible to 
participate in Part 1 of the study.
For women of childbearing potential:  agreement to remain abstinent (refrain from heterosexual 
intercourse) or use contraceptive methods that result in a failure rate of 1% per year during the 
treatment period and for at least 16 weeks after the last dose of study drug.
A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached 
a postmenopausal state (12 continuous months of amenorrhea with no identified cause other 

Gantenerumab —F. Hoffmann-La Roche Ltd
14/Protocol WN41874, Version 2
than menopause), and has not undergone surgical sterilization (removal of ovaries, fallopian 
tubes, and/or uterus).
Examples of contraceptive methods with a failure rate of 1% per year include bilateral tubal 
ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing 
intrauterine devices, and copper intrauterine devices.
The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical 
study and the preferred and usual lifestyle of the participant.  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable 
methods of contraception.
Eligible participants provide written consent signed by them or by the participant’s legally 
authorized representative before his or her participation in the study (in accordance with 
applicable laws and Institutional Review Board/Ethics Committee policy).
Agreement to not donate blood or blood products for transfusion for the duration of the study 
and for 1 year after final dose of study drug will be needed for all participants. 
Availability of a person (referred to as the “caregiver” throughout this protocol) who in the 
investigator’s judgement, has frequent and sufficient contact with the participant.
Exclusion Criteria
Participants who met any of the following criteria will not be eligible:  

Prematurely discontinued from the OLEs of Studies WN25203 or WN28745 or from study 
drug for any reason 

Any medical condition that the investigator or Sponsor determines may jeopardize the 
participant’s safety if he or she continues to receive study treatment

If the participant is unlikely to benefit from gantenerumab therapy, based on disease 
progression or other factors, or if study participation is otherwise not in the participant’s best 
interest, by determination of the investigator or Sponsor

Any investigational treatment other than gantenerumab during or since completion of the 
OLEs of Studies WN25203 or WN28745

Pregnancy

Evidence of disseminated leptomeningeal hemosiderosis (i.e., more than three focal 
leptomeningeal hemosiderosis)

Evidence of intracerebral macrohemorrhage
Eligibility in Part 2

All participants who have completed Week 104 visit in Part 1 of the study and have not 
been discontinued from Part 1 of the study can continue to participate in Part 2 of the 
study

The criteria mentioned in Inclusion Criteria and Exclusion Criteria will also be applicable
to Part 2 of the study
End of Study
The end of study is defined as the date when the last participant, last visit (LPLV) occurs or the 
date on which the last data point required for safety follow-up is received from the last 
participant in the study, whichever is later.
Length of Study
The study will consist of open-label treatment for 2 years beyond the initial 2 years, with a 
4 week post-treatment follow-up period.
Investigational Medicinal Products
For Part 1, all participants will receive the same dose of gantenerumab SC Q4W as the last 
dose received in the qualifying studies, either 1200 mg or 900 mg.  
For Part 2, all participants will continue to receive the same dose of gantenerumab SC Q4W 
as the last dose received in Part 1 of the study.

Gantenerumab —F. Hoffmann-La Roche Ltd
15/Protocol WN41874, Version 2
At applicable sites, study drug may be administered by a trained nursing professional at the
participant's home or another suitable location, if the participant has given written informed 
consent to participate in mobile nursing visits.
Non-Investigational Medicinal Products
Participants will be permitted to receive any treatment deemed necessary by the investigator for 
the management of their disease, with the exception of any other disease-modifying drug for AD.
Statistical Methods
Participant disposition (including withdrawals from treatment), protocol deviations, demographic 
and baseline characteristics (such as age, sex, race, disease stage, and APOE 4 status) will 
be summarized descriptively for all participants in the safety population who receive at least one 
dose of treatment in this study.  
To monitor AD progression, MMSE will be summarized using mean, SD, median, inter-quartile 
range, and minimum and maximum. No hypothesis testing will be performed.
Safety Analyses
The safety analysis population will include all participants who received at least one dose of 
study drug.  The following safety outcome measures will be summarized using descriptive 
statistics:

Incidence, nature, severity, and timing of adverse events

Incidence, nature, severity, and timing of serious adverse events

Changes from baseline of this study in vital signs, blood tests, ECGs, and Columbia-Suicide 
Severity Rating Scale (C-SSRS)

Incidence, nature, severity, and timing of magnetic resonance imaging (MRI) safety findings:  
amyloid related imaging abnormalities-edema/effusion (ARIA-E) and amyloid-related 
imaging abnormalities-hemosiderin deposition (ARIA-H)

Incidence, nature, severity, and timing of injection-site reactions (ISRs)

Number and proportion of anti-drug antibody (ADA)-positive and ADA-negative participants 
during both the treatment and follow-up periods

Incidence of treatment discontinuations for adverse events

Incidence of adverse events of special interest 
Determination of Sample Size
For Part 1, the sample size was determined by the number of participants who complete the 
OLE part of Studies WN25203 or WN28745 and subsequently enrolled in this study.  There 
were 116 participants that participated in Part 1 of the study.
For Part 2, the sample size is expected to be no more than 116 participants. 
Interim Analyses 
No interim analyses will be planned for this study. 

Gantenerumab —F. Hoffmann-La Roche Ltd
16/Protocol WN41874, Version 2
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS
Abbreviation
Definition
A
amyloid-
AD
Alzheimer’s disease
ADA
anti-drug antibody
APOE
apolipoprotein E
ARIA
amyloid-related imaging abnormality
ARIA-E
amyloid-related imaging abnormality–edema/effusion
ARIA-H
amyloid-related imaging abnormality–hemosiderin depositions
BP
blood pressure
COVID-19
coronavirus disease 2019
CRF
Case Report Form
C-SSRS
Columbia-Suicide Severity Rating Scale
DIAN-TU
Dominantly Inherited Alzheimer Network Trial
EC
Ethics Committee
eCRF
electronic Case Report Form
EDC
electronic data capture
GCP
Good Clinical Practice
GRE
gradient recalled echo
HIPAA
Health Insurance Portability and Accountability Act
IB
Investigator's Brochure
ICF
Informed Consent Forms
ICH
International Conference for Harmonization of Technical Requirements 
for Registration of Pharmaceuticals for Human Use
IMC
Internal Monitoring Committee
IMP
investigational medicinal product
IND
Investigational New Drug
IRB
Institutional Review Board
ISR
injection-site reaction
IxRS
interactive voice/web response system
IV
Intravenous
LAR
legally authorized representative
LPLV
last participant, last visit
MAD
multiple-ascending dose
MMSE
Mini Mental State Examination
MN
mobile nursing

Gantenerumab —F. Hoffmann-La Roche Ltd
17/Protocol WN41874, Version 2
Abbreviation
Definition
MRI
magnetic resonance imaging
OLE
open-label extension
PD
Pharmacodynamics
PET
positron emission tomography
PI
Principal Investigator
PK
Pharmacokinetic
PK-PD
pharmacokinetic-pharmacodynamic
Q4W
every 4 weeks
RBR
Research Biosample Repository
SC
Subcutaneous
SUVr
standardized uptake value ratio 
ULN
upper limit of normal

Gantenerumab —F. Hoffmann-La Roche Ltd
18/Protocol WN41874, Version 2
1.
BACKGROUND
1.1
BACKGROUND ON ALZHEIMER’S DISEASE
The WHO estimates that approximately 50 million people worldwide are living with 
dementia and that 10 million new cases are diagnosed every year. The total number of 
people with dementia is estimated to reach 82 million in 2030 and will almost triple to 
152 million by 2050. Alzheimer’s disease (AD) is the most common form of dementia, 
accounting for 60%70% of cases (WHO 2017). The prevalence of AD increases with 
age, with a global prevalence of 5%8% in people aged 60 years or over.
AD is clinically characterized by a progressive impairment in cognitive and executive 
abilities, which results in decreased function and gradual loss of independence 
(Mesterton et al. 2010). There is great inter-individual variability in AD progression with 
survival dependent on many factors, including age at onset. In general, the clinical 
picture evolves from "predementia" or "prodromal AD" to mild, moderate, and then 
severe AD. At the early stage of AD, a slight impairment of memory, language, and 
visuospatial function can be observed. As AD advances, patients become progressively 
impaired and the burden on caregivers significantly increases. The median survival time 
following a diagnosis of AD depends on the patient’s age at diagnosis and ranges from 
8.3 years for persons diagnosed with AD at 65 years old to 3.4 years for those 90 years 
old (Brookmeyer et al. 2002). On average, individuals live 6 years after diagnosis 
(Helzner et al. 2008).
Pathologically, AD is characterized by the presence of cerebral amyloid-(Aplaques, 
neurofibrillary tangles, and a loss of neurons. Ais a peptide derived from proteolytic 
processing of the amyloid precursor protein. This peptide exists in two major forms: 
A1-40 and A1-42 (Citron 2004). Although the etiology of AD is not completely 
understood, current research suggests that Aprocessing and deposition play a critical 
role in the cascade of biological events involved in the pathogenesis of the disease. 
Consequently, therapies targeting this process have the potential to significantly alter the 
progression of the disease.
Because of ADs increasing prevalence, long duration, and high cost of care, it is 
expected to continue to represent a major public health problem for decades to come.
1.2
BACKGROUND ON GANTENERUMAB 
Gantenerumab (or RO4909832) is a fully human antiApeptide antibody developed by 
in vitro selection utilizing aggregated Aand in vitro maturation within a complete human 
Ig, subclass-1 framework (immunoglobulin G1).  Gantenerumab recognizes a 
conformational epitope of Apresent in aggregated Aand that is demonstrated for both 
major species of Athat is, A1−40 and A1−42.  Gantenerumab has a molecular mass of 
146.3 kDa.  In vitro, gantenerumab recognizes synthetic aggregated Afibrils and 
Aoligomers with high nanomolar affinity (KD, ~0.61.2 nM).  Based on additional in vitro 
studies and studies in animal models, the pharmacologic profile suggests that in humans,

Gantenerumab —F. Hoffmann-La Roche Ltd
19/Protocol WN41874, Version 2
gantenerumab may prevent, inhibit, and reduce accumulation of A, which is believed to 
play an important role in the pathogenesis of AD.  
Gantenerumab is manufactured by cell culture of a recombinant Chinese hamster 
ovaryK1 mammalian cell line and subsequent purification of the antibody.  The 
gantenerumab drug substance manufacturing was optimized during development, 
leading to several manufacturing processes (G1, G2, G3, and G4). In this study, G3 
material will be used.  Gantenerumab is in clinical development for participants with early 
(prodromal to mild) AD and is also being investigated in carriers of familial AD mutations 
(Dominantly Inherited Alzheimer Network Trial [DIAN-TU]) (Bateman et al. 2017).
Refer to the Gantenerumab Investigator's Brochure (IB; version 15, July 2019) for details 
on nonclinical and clinical studies.
1.2.1
Clinical Studies
Gantenerumab has been investigated in 10 completed Phase I clinical studies:  three 
single-ascending dose studies (BN18726, JP22474, and BP30042) of healthy volunteers
and participants with mild to moderate AD, two multiple-ascending dose (MAD) studies 
(NN19866 and JP22431) of participants with mild to moderate AD, and four 
bioavailability studies of healthy subjects (one comparing the intravenous [IV] and 
subcutaneous [SC] formulations of gantenerumab [Study WP22461], two comparing 
lyophilized and high-concentration liquid formulations of gantenerumab 
[Studies WP27951 and BP29113], and one comparing G3 and G4 material 
[Study WP40052]).  In addition, a tolerability study comparing the pain between faster 
and slower SC administrations of gantenerumab has been completed (Study WP39322). 
Gantenerumab has also been investigated in two Phase III studies that have been 
converted to open-label extension (OLE) studies: WN25203 and WN28745. 
Two additional Phase III studies (WN29922 and WN39658) investigating the effect of 
gantenerumab in prodromal to mild AD are ongoing.
A total of 543 participants have participated in the Phase I studies; of these, 406 healthy 
volunteers and 101 participants with AD have received gantenerumab.  
In addition, gantenerumab is being investigated in Dominantly-Inherited Alzheimer’s 
Network Trials Unit (DIAN-TU-001), a Phase II/III study sponsored by Washington 
University School of Medicine. The double-blind, placebo-controlled part of a 
Phase II/III study, the DIAN-TU-001 concluded (last participant, last visit [LPLV]: 
6 March 2020). The DIAN-TU-001 was designed to test the effects of gantenerumab, 
solanezumab, or JNJ-54861911 versus placebo in individuals at risk for early-onset AD 
caused by a genetic mutation (i.e., Dominantly-Inherited Alzheimer’s disease). The 
objective of the study was to assess the safety, tolerability, biomarker, and cognitive 
efficacy of the treatments after 4 years of treatment. The OLE portion of the study, 
which includes only gantenerumab treatment, is ongoing.

Gantenerumab —F. Hoffmann-La Roche Ltd
20/Protocol WN41874, Version 2
Results of relevant studies are summarized below.  Refer to the gantenerumab IB for 
further information.
1.2.1.1
Study NN19866
In the MAD study (NN19866), a total of 60 participants (34 males and 26 females) 
diagnosed with mild to moderate probable AD received multiple IV doses of 
gantenerumab (doses ranging from 6 mg, 20 mg, 60 mg, and 200 mg) or placebo every 
4 weeks (Q4W) for up to 7 months.  Owing to amyloid-related imaging abnormalities 
(ARIAs), or ARIAs of "vasogenic edema" (ARIA-E) and of "hemosiderosis or 
microbleeds" (ARIA-H), on brain magnetic resonance imaging (MRI) scans that occurred 
in some participants after two to four doses of 200 mg of gantenerumab in Cohort 4 
(200 mg IV Q4W gantenerumab [equivalent to 330 mg SC Q4W] or placebo), it was 
decided to terminate dosing for all participants on 9 June 2008.  The findings resolved 
spontaneously within 14 months after discontinuation of gantenerumab and no 
participant required treatment. 
1.2.1.1.1
Study NN19866:  Pharmacodynamic Results in the NN19866
PET-Substudy
In a positron emission tomography (PET) substudy of Study NN19866 (NN19866-PET), 
the effects of gantenerumab on amyloid load in the brain (defined as standardized 
uptake value ratio [SUVr] of a cortical composite volume of interest over mean 
cerebellum gray and using 11C-PiB PET) were evaluated in 18 participants (4 in the 
placebo group, 8 in the 60-mg IV gantenerumab dose group, and 6 in the 200-mg IV 
gantenerumab dose group) after 6 months.  A mean decrease of 14.9% from baseline 
was observed in the 200-mg gantenerumab dose group, whereas an increase was seen 
in the placebo group (mean, 20.9%), with relative stability compared with baseline in the 
60-mg group (mean, 5.3%) (Ostrowitzki et al. 2012).
1.2.1.2
Study WN25203
Based on the results from Study NN19866 and a relative bioavailability study WP27951, 
the doses of 105 mg SC Q4W (equivalent to 60 mg IV Q4W) and 225 mg SC Q4W 
(equivalent to 130 mg IV Q4W) were selected for Study WN25203.  Study WN25203 
was designed as a Phase III, randomized, double-blind, placebo-controlled, 
parallel-group, multicenter study to evaluate the safety and efficacy of 105 mg and 
225 mg of gantenerumab administered subcutaneously Q4W in prodromal AD after two 
years of treatment.  Randomization was based on apolipoprotein E (APOE 4), allele 4 
status.  Selection of gantenerumab doses was largely driven by the objective of reducing 
risk of MRI findings (in the context of the clinical understanding of ARIAs at the time of 
study design) and by pharmacodynamic (PD) results in the MAD Study NN19866.  
Study WN25203 enrolled 799 participants, and 797 participants were treated (the 
safety-evaluable population). 
The results of the preplanned futility analysis of data from approximately 300 participants 
in Study WN25203 revealed the low likelihood for study success with the original doses 

Gantenerumab —F. Hoffmann-La Roche Ltd
21/Protocol WN41874, Version 2
studied.  Though no significant differences were observed on clinical outcome measures, 
additional post-hoc analyses strongly suggested that the doses studied in 
Study WN25203 (105 and 225 mg) were subtherapeutic and that a higher gantenerumab 
dose may have a clinically relevant effect (Ostrowitzki et al. 2017). 
These post-hoc analyses supported the rationale of converting the study into an OLE 
with higher doses. 
1.2.1.3
Study WN28745
Study WN28745 was initially designed as a Phase III, 2-year, double-blind, 
placebo-controlled, efficacy, and safety study of gantenerumab in approximately 
1000 participants with mild AD.  Participants randomized to receive gantenerumab were 
to follow a slow titration scheme independent of APOE-4 genotype, starting at 105 mg 
of SC gantenerumab Q4W for the first 24 weeks, with progression to 225 mg, based on 
acceptable results of the control MRI scan.  The study enrolled 389 participants, and 
387 participants were treated.  There were 108 participants also enrolled in a PET 
substudy of brain amyloid imaging (Study WN28745-PET).  Following the 
Study WN25203 futility analysis, study recruitment was stopped and the study was 
converted to an OLE study, evaluating the safety and tolerability of gantenerumab at 
higher doses (up to 1200 mg).
1.2.1.4
OLE Studies WN25203 and WN28745 
Both the WN25203 and WN28745 studies were converted to OLE studies to evaluate
the long-term safety of higher dose administration of gantenerumab.  Doses up to 
1200 mg SC Q4W of gantenerumab were tested, using titration regimens designed to 
minimize the risk of ARIA and taking into account the APOE genotype and the previous 
double-blind treatment and dose.
The PET substudy also continued in the OLE Studies WN25203 and WN28745 to 
evaluate target engagement of the higher dose of gantenerumab. The study showed 
higher reductions of amyloid plaque over a shorter time period with the 1200 mg dosing 
regimen of gantenerumab compared with 105 or 225 mg dosing. Results from this study 
confirm the amyloid plaque removal component of the gantenerumab mechanism of 
action, which is more prominent with high dose administration. Following two years of 
treatment, approximately 50% of subjects achieved below threshold PET SUVr signals
based on quantitative measures, and 74% of subjects were below threshold after 
three years of treatment. Refer to the gantenerumab IB for further details.
Both of the double blind and OLE studies of WN25203 and WN28745 have been closed. 
A total of 385 participants had been enrolled in the OLE Studies WN25203 and 
WN28745, with 363 participants exposed to G3 gantenerumab doses higher than 
225 mg (i.e., more than the highest repeat dose previously tested in participants with AD) 
and 255 participants having reached the OLE target 1200 mg dose.  Injection-site 
reactions (ISRs) and ARIAs remain the identified risks for gantenerumab.  Safety data 

Gantenerumab —F. Hoffmann-La Roche Ltd
22/Protocol WN41874, Version 2
and MRI findings have been monitored by Internal Monitoring Committee, which has not 
identified any new safety signal in these studies.
Refer to the gantenerumab IB for details on nonclinical and clinical studies.
1.2.2
Safety Overview 
Nonclinical characterization of gantenerumab did not show any relevant safety findings.  
To date, ARIAs and ISRs are the identified risks for gantenerumab. No differences 
between active and placebo groups have been observed in laboratory parameters, 
physical and neurological examinations, vital signs, or ECG parameters.
Gantenerumab has been generally safe and well-tolerated in healthy volunteers and
participants with AD.
The identified risks of gantenerumab treatment are ARIA-E and of ARIA-H, and ISRs. 
Both of the double blind and OLE studies of WN25203 and WN28745 have been closed 
and data monitoring for these studies has been completed. Safety data and MRI findings 
from the OLEs of Studies WN25203 and WN28745 were continuously monitored and no 
new safety signals were identified in these studies where gantenerumab has been 
administered in doses of up to 1200 mg SC Q4W.
A summary of safety data with gantenerumab SC in participants with AD from 
Studies WN25203 and WN28745, up to the cutoff date of 1 May 2019, is presented 
below. 
Data from Study JP22431 is presented in Section 5.5.2.1 of the IB, and data from 
healthy volunteer studies with gantenerumab SC and studies with gantenerumab IV is 
presented in Section 5.5.1 of the gantenerumab IB. 
Overview of Adverse Events
In the double-blind part of Study WN25203, gantenerumab, in doses of 105 mg or 
225 mg SC Q4W for up to 3.9 years was safe and well-tolerated by participants with 
prodromal AD. Adverse events were reported for 94.0%, 88.9%, and 92.3% of 
participants in the placebo, gantenerumab 105 mg, and gantenerumab 225 mg groups, 
respectively. Similarly, in Study WN28745, gantenerumab at a dose of 105 mg SC Q4W 
for 6 months followed by 225 mg SC Q4W for up to 24 months was safe and 
well-tolerated by participants with mild AD. Adverse events were reported in 80.5% and 
82.8% of participants in the placebo and gantenerumab groups, respectively.
In the OLE of Studies WN25203 and WN28745 (snapshot date11 January 2021),
gantenerumab, in doses of up to 1200 mg SC Q4W for up to approximately 156 weeks 
(~3 years), was safe and well-tolerated by participants with AD. In the OLE phase of 
Study WN25203, 1750 adverse events were reported in 146 of 154 participants (94.8%), 

Gantenerumab —F. Hoffmann-La Roche Ltd
23/Protocol WN41874, Version 2
and 2113 adverse events were reported in 209 of 225 participants (92.9%) in 
Study WN28745.
MRI Findings of Amyloid-Related Imaging Abnormalities
In the double-blind part of Study WN25203, ARIA events were dependent on time
(duration of treatment), dose, and APOE ε4 allele status. The frequency of ARIA-E 
MRI findings was 0.8%, 6.6%, and 13.5% and the frequency of ARIA-H was 13.2%, 
22.9%, and 16.2% in the placebo, 105-mg gantenerumab, and 225-mg gantenerumab 
groups, respectively.
Generally, ARIA events were asymptomatic and resolved spontaneously; discontinuation
due to protocol-mandated rules for ARIA-E or ARIA-H occurred in less than 5% of
participants.
In the double-blind part of Study WN28745, the frequency of new ARIA-E was 1.5% and 
11.5% and the frequency of ARIA-H was 11.8% and 15.1% in the placebo and
gantenerumab groups, respectively. Most ARIAs were asymptomatic and did not lead to
clinically significant consequences. One participant (0.5%) in the placebo and
gantenerumab groups each reported symptoms related to ARIA, which were mild to 
moderate and non-serious. Discontinuation due to protocol-mandated rules for ARIA-E 
or ARIA-H occurred in approximately 3.4% of participants.
In the OLE part of Study WN25203, all 154 participants dosed with gantenerumab in the 
OLE had at least one post-OLE baseline MRI scan. Of these, 47 participants (30.5%) 
had new ARIA-E and 51 participants (33.1%) had new ARIA-H. Additionally, 
31 participants (20.1%) had new ARIA-E and new ARIA-H at any point during the 
OLE.  The CNS adverse events temporally associated ARIA-E MRI findings were 
mostly non-serious, mild to moderate in intensity, and resolved spontaneously with
protocol-defined ARIA management rules. None of these adverse events led to 
permanent discontinuation of study treatment.
In OLE part of the Study WN28745 and up to snapshot date of 11 January 2021, 219 of 
225 participants dosed with gantenerumab in the OLE phase had a post-baseline MRI 
scan.  Of these, 71 participants (32.4%) had new ARIA-E and 75 participants (34.24%) 
had new ARIA-H. Additionally, 49 participants (22.37%) had new ARIA-E and 
ARIA-H at any point during the OLE.  The CNS adverse events were mostly mild to 
moderate in intensity, non-serious, did not require permanent cessation of study 
treatment, and resolved spontaneously with protocol-defined ARIA management rules.  
None of these adverse events led to permanent discontinuation of study treatment.
To minimize ARIA occurrence, the highest dose level is reached with a gradual 
up-titration; ARIA-E incidence observed in the OLEs has been in the expected range and 
in alignment with the ARIA-E pharmacokinetic-pharmacodynamic (PK-PD) model 

Gantenerumab —F. Hoffmann-La Roche Ltd
24/Protocol WN41874, Version 2
(see Section 5.1 of the Gantenerumab IB). ARIA-E events are clinically manageable by 
protocol-defined MRI monitoring and dose intervention algorithms.
Injection-Site Reactions
In the double-blind part of Study WN25203, the incidence of ISRs was 4.5%, 18.8%, and 
23.1% in the placebo, 105-mg gantenerumab, and 225-mg gantenerumab group,
respectively. In the double-blind part of Study WN28745, the incidence of ISRs was 1.0% 
and 9.4% in the placebo and gantenerumab groups, respectively. The most common 
ISR was erythema.
In the OLE phase of Studies WN25203 and WN28745 (snapshot date11 January 2021), 
ISRs have been reported in 36.4% of participants (56 of 154) in Study WN25203, and 
40.0% of participants (90 of 225) in Study WN28745.  Overall, 5.4% of participants (3 of 
56) in the OLE of Study WN25203 and 11.1% of participants (10 of 90) in the OLE of 
Study WN28745 who had ISR received treatment, which included topical steroids and 
antihistamines.
In both studies, across phases, all ISRs were non-serious, most were of mild intensity 
and resolved without requiring treatment.  The most common ISR was erythema, both 
in the double-blind phase and the OLE phase of Studies WN25203 and WN28745.
Refer to the gantenerumab IB for safety data from all studies.  
1.3
STUDY RATIONALE AND BENEFITRISK ASSESSMENT
Currently, approved therapies for AD focus on symptomatic approaches that target 
synaptic function and cognitive enhancement (Cummings 2004).  However, the amyloid 
hypothesis suggests that overproduction of Aor failure to effectively clear this peptide 
contributes to AD (Selkoe and Hardy 2016) and that accumulation of Apeptides is one 
factor contributing to AD progression (Sun et al. 2015).  Thus, the targeting of Aand 
subsequent displacement of Afrom the brain is a rational approach to modify AD 
progression.
Despite compelling results in AD animal models (Wisniewski and Goñi 2014), clinical 
success with passive immunization targeting brain amyloid in global Phase III studies
remains an unachieved goal.  It has been suggested that lack of sufficient target 
engagement of anti-amyloid antibodies has been a factor in the failure of these Phase III 
studies (Cummings et al. 2016).  An important advancement for therapies targeting 
aggregated amyloid was provided based on data from the Phase Ib PRIME study of 
aducanumab (Biogen) (Sevigny et al. 2016). 
Accumulating clinical evidence also supports that monoclonal Aβ antibodies can bind Aβ 
and promote its clearance (Salloway et al. 2009; Ostrowitzki et al. 2012; 
Sevigny et al. 2016; Klein et al. 2017), reduce deposition of Aβ aggregates, and reduce 

Gantenerumab —F. Hoffmann-La Roche Ltd
25/Protocol WN41874, Version 2
markers of neurodegeneration in the cerebral spinal fluid (Ostrowitzki et al. 2017). A 
Phase I study of aducanumab (Sevigny et al. 2016) and a Phase II study of BAN2401 
(Swanson et al. 2018) suggested that reduction of deposited amyloid, as seen on brain 
amyloid PET imaging was associated with a dose-related slowing of cognitive decline. 
1.3.1
Study Rationale
The rationale of this study is to continue to collect long-term safety and tolerability data 
in participants with AD treated with gantenerumab.
The rationale of continuous administration of gantenerumab is supported by data from 
the PET substudy in the OLE Studies WN25203 and WN28745 that showed continuous 
reduction of the amyloid plaque component beyond two years of treatment. 
1.3.2
Rationale for Dosing Strategy 
Rationale for the Dosing Strategy in Part 1
All participants received the same dose of gantenerumab SC Q4W as the last dose 
received in the qualifying studies, either 1200 mg or 900 mg. Participants who had a 
dose gap between the last visit from the WN25203/WN28745 OLE and this study, 
depending on the actual duration of the dosing gap and their ARIA history, may be 
asked to start with a lower dose, as detailed in Appendix 3 and then be up-titrated to the 
target dose.
Rationale for the Dosing Strategy in Part 2
All participants will continue to receive the same dose of gantenerumab SC Q4W as the 
last dose received in Part 1 of the study.
1.3.3
Overall BenefitRisk Summary
Overall, the benefit-risk assessment of gantenerumab is based on the following:

Gantenerumab has shown evidence of reducing amyloid plaques (i.e., observed 
evidence of brain amyloid reduction, see Section 1.2.1.4) and, thus, shows potential 
benefit in slowing the progression of AD.

Findings from the WN25203 and BAN2401 studies (Swanson et al. 2018) provide 
additional support for the hypothesis that anti-amyloid treatment may be associated 
with a beneficial clinical effect.

Results from the double-blind part of Studies WN25203 and WN28745, as well as 
from the OLEs of Studies WN25203 and WN28745, showed that ARIA-E findings 
are mostly asymptomatic, non-serious, of mild severity, and do not require 
permanent cessation of treatment.  ARIAs are manageable with MRI monitoring and 
dose intervention algorithms, as detailed in Section 5.1.2.

No new safety signal has been identified in data from the OLEs of 
Studies WN25203 and WN28745 with doses of up to 1200 mg Q4W.  These data 
support the continued administration of gantenerumab at doses up to 1200 mg Q4W
in both APOE 4 carriers and non-carriers in this study.

Gantenerumab —F. Hoffmann-La Roche Ltd
26/Protocol WN41874, Version 2

Based on its mechanism of action, there is no reason to believe that gantenerumab 
administration would compromise the immunologic reaction of the body. This is 
supported by the nonclinical and clinical data collected through the development 
program of gantenerumab, where there has been no indication that gantenerumab 
administration compromised immune system or made individuals more susceptible 
to infections. Thus, there are no data or biological rationale suggesting that 
gantenerumab administration could increase the risk of infection by severe acute 
respiratory syndrome coronavirus 2 or more severe coronavirus disease 2019 
(COVID-19) outcomes. Whereas people with AD, because of advanced age, may be 
in a higher-risk group for COVID-19, participation in Study WN41874 is not 
expected to increase that risk.

Based on the available information, no interactions between gantenerumab and the 
COVID-19 vaccines are expected to occur, and no other safety concerns have been 
identified that would prohibit the vaccination of participants enrolled in the studies 
where gantenerumab is being investigated for the treatment of AD. Just as with 
other vaccinations (e.g., influenza), the administration of COVID-19 vaccines will 
be considered as a concomitant medication in this study.
Overall, the benefitrisk profile of gantenerumab supports open-label gantenerumab
treatment in Study WN41874 for participants who completed the OLE parts of 
Study WN25203 or WN28745. 
2.
OBJECTIVES AND ENDPOINTS
The main objective of this study (Part 1 and Part 2) is to continue to collect long-term 
safety and tolerability data in participants with AD treated with gantenerumab. Specific 
objectives and corresponding endpoints for the study are outlined in Table 1.
Table 1
Objectives and Corresponding Endpoints
Safety Objective
Corresponding Endpoints
To evaluate the long-term safety and 
tolerability of continued treatment 
with SC gantenerumab at target 
dose in participants with AD who 
received gantenerumab in OLEs of 
Studies WN25203 or WN28745
Nature, frequency, severity, and timing of AEs and 
SAEs
Physical examinations (including neurological 
systems), vital signs, blood tests, ECGs, and C-SSRS
Nature, frequency, severity, and timing of MRI 
findings:  ARIA-E and ARIA-H
Nature, frequency, severity, and timing of injection-site 
reactions
Immunogenicity of long-term treatment with 
gantenerumab through the measurements of ADAs 
Incidence of treatment discontinuations for AEs
Incidence of AEs of special interest
Exploratory Efficacy Objective
Corresponding Endpoint
To assess the long-term clinical 
effect in participants with AD
MMSE total score will be used to assess AD 
progression

Gantenerumab —F. Hoffmann-La Roche Ltd
27/Protocol WN41874, Version 2
Table 1
Objectives and Corresponding Endpoints (cont.)
Exploratory Pharmacodynamic
Biomarker Objective
Corresponding Endpoints
To evaluate the long-term effect of 
gantenerumab in participants with 
AD
MRI-derived measurements over time, such as 
volumetric changes in whole brain, ventricles, 
hippocampus, or other structures, in all participants
Plasma pharmacodynamic biomarkers over time
ADAlzheimer's disease; ADAanti-drug antibodies; AEadverse event; 
ARIA-Eamyloid-related imaging abnormalitiesedema/effusion; ARIA-Hamyloid-related 
imaging abnormalitieshemosiderin deposition; C-SSRSColumbia-Suicide Severity Rating 
Scale; ECGelectrocardiogram; MMSEMini Mental State Examination; MRImagnetic 
resonance imaging; OLEopen-label extension; SAE serious adverse event; 
SCsubcutaneous
3.
STUDY DESIGN
3.1
DESCRIPTION OF THE STUDY
3.1.1
Overview of Study Design in Part 1
This is an open-label, multicenter, rollover study to evaluate the safety and tolerability of 
long-term administration of gantenerumab in participants with AD.
All participants who had completed the OLEs of Studies WN25203 or WN28745 were
eligible to participate in this study. Participants, who discontinued early from study 
treatment during Study WN25203 or WN28745, regardless of the reason, were not 
eligible for this study.
Informed consent was obtained by participants while they were active in the qualifying 
study. In the case of protocol approval delays, informed consent could be obtained at a 
later timepoint, but before any study procedures in this study are performed.
The first administration of gantenerumab in this part of the study will be considered the 
baseline visit and, whenever possible, should coincide with the first post-treatment 
follow-up visit of OLEs of Studies WN25203 or WN28745. The data of the follow-up 
assessments will be used as baseline data for this study if they take place on the same 
day or within a period of 4 weeks. Magnetic resonance imaging, Mini Mental State 
Examination (MMSE), and Columbia-Suicide Severity Rating Scale (C-SSRS) do not 
need to be repeated if the baseline occurs in less than 6 months from the final follow-up 
visit in the previous parent study. MRI and urine pregnancy test results should be 
available before dosing.
In this study, participants will continue receiving open-label gantenerumab by SC 
injection Q4W at the same dose as administered in the parent Studies WN25203 or 
WN28745. There is a7 day window for all visits. However, the minimal time between 
doses is 21 days, and the target day for each Q4W visit is timed with respect to baseline, 
not to the prior visit.

Gantenerumab —F. Hoffmann-La Roche Ltd
28/Protocol WN41874, Version 2
Participants who had a dose gap between the last visit from the WN25203/WN28745 
OLE and this study (Part 1), depending on the actual duration of the dosing gap and 
their ARIA history, may be asked to start with a lower dose, as detailed in Appendix 3.
In the case that a participant had at the baseline visit an ARIA-E that was ongoing since 
the parental study, there was a continuity of ARIA management between the two studies, 
and ARIA management rules as described in Appendix 2 will apply.  
Participants will be treated for 2 years, followed by a safety and MMSE assessment 
4 weeks following the last dose (follow-up visit; see Schedule of Activities).  
Participants who discontinue study drug at any time during this study will be asked to 
complete an early termination visit 4 weeks after their last dose (early termination visit; 
see Appendix 1).
3.1.2
Overview of the Study Design in Part 2
All participants who are actively enrolled in Part 1 of Study WN41874 (i.e., have 
completed Week 104 visit in Part 1 and have not discontinued from study drug per
Section 4.6.1) will be invited to participate in Part 2 of the study. 
Informed consent should be obtained by participants while they are active in the Part 1 
of the study.  
In Part 2 of the study, participants who have previously completed the Week 104 visit, 
(i.e., without having to perform a follow up visit post Week 104 in Part 1) can continue 
receiving open-label gantenerumab for additional 2 years. Additionally, participants 
might also have an option of participating in another open label extension study while 
completing the Part 2 of the study.
Gantenerumab will be administered by SC injection Q4W at the same dose as 
administered in the Part 1 of the study.  There is a 7 day window for all visits.  
However, the minimal time between doses is 21 days, and the target day for each Q4W 
visit is timed with respect to baseline, not to the prior visit. 
Participants will be treated for an additional 2 years, followed by a safety and MMSE 
assessment 4 weeks following the last dose (follow-up visit; see Appendix 1). 
Participants will undergo tests of safety, efficacy as per the schedule of assessments.
The end of the study will be considered as the follow-up visit 4 weeks after the last dose 
for the last participant that enrolled over to Part 2.
All participants have the right to voluntarily discontinue study drug or withdraw from 
the study at any time for any reason.

Gantenerumab —F. Hoffmann-La Roche Ltd
29/Protocol WN41874, Version 2
Participants who discontinue study drug at any time during this study will be asked to 
complete a follow-up visit at 4 weeks after their last dose (early termination visit; see
Appendix 1).
Participants who do not want to participate in Part 2 of the study will be discontinued 
from the study and will be asked to complete follow up visit 4 weeks after the last dose as 
per the Schedule of Assessments (follow up visit; see Appendix 1).
3.1.3
Internal Monitoring Committee 
For Part 1 and Part 2
During the study, the nature, frequency, severity, and timing of adverse events, serious 
adverse events, ARIA-E and ARIA-H findings, ISRs, and laboratory and other test 
abnormalities will be assessed on a regular basis by an IMC.
3.2
END OF STUDY AND LENGTH OF STUDY
The end of the study is defined as the date when the LPLV occurs or the date on which 
the last data point required for safety follow-up is received from the last participant in the 
study, whichever is later. 
3.3
RATIONALE FOR STUDY DESIGN
3.3.1
Rationale for Gantenerumab Dose and Schedule Part 1
All participants will receive the same dose of gantenerumab SC Q4W as the last dose 
received in the qualifying studies, either 1200 mg or 900 mg.
Participants who had a dose gap between the last visit from the OLEs of 
Studies WN25203/WN28745 and Part 1 of the study due to unforeseen circumstances, 
depending on the actual duration of the dosing gap and their ARIA history, may be 
asked to start with a lower dose, as detailed in Appendix 3. Before up-titration to the 
target dose, three administrations of a lower dose have to take place.
Rationale for Gantenerumab Dose and Schedule Part 2
All participants will continue to receive the same dose of gantenerumab SC Q4W as the 
last dose received in Part 1 of the study.
3.3.2
Rationale for Participant Population
In Part 1, participants with AD who had completed the OLEs of Studies WN25203 or 
WN28745 were eligible to participate in Part 1 of the study, to evaluate long-term safety 
and tolerability of gantenerumab. Thus, per eligibility criteria for this study, all 
participants who had completed the OLEs of Studies WN25203 or WN28745 and meet 
all the eligibility criteria, were able to participate in the study.
In Part 2, participants with AD who have completed the Week 104 visit in Part 1 and 
have not discontinued from study drug per Section 4.6.1, will be given the option to 

Gantenerumab —F. Hoffmann-La Roche Ltd
30/Protocol WN41874, Version 2
continue to participate in Part 2 of the study, to evaluate long-term safety and 
tolerability of gantenerumab
3.3.3
Rationale for Key Endpoints (Part 1 and Part 2)
The primary objective of this study is to collect long-term safety and tolerability data for 
gantenerumab.
3.3.4
Rationale for Study Treatment Duration
This study will continue providing gantenerumab to the participants who completed the 
OLEs of Studies WN25203 or WN28745, and Part 1 of Study WN41874 for an 
additional 2 years beyond the initial 2 years to collect long-term safety and tolerability 
data for gantenerumab. 
3.3.5
Rationale for Biomarker Assessments
Biomarker assessments will be used to investigate, in an exploratory fashion, the effect 
of gantenerumab on the underlying pathology of AD in the clinical study population.
3.3.5.1
Blood Biomarkers
Blood samples will be obtained from all participants and will be used for research 
purposes to identify dynamic biomarkers that may help to understand the response to 
treatment with gantenerumab (in terms of dose, safety, and tolerability) and will help to 
better understand the pathogenesis, course, and outcome of AD and related diseases.
Roche may keep information about test results, medical history, and demographic 
information for all participants for future development of diagnostic tests related to A, 
APOE genotype, and AD, as well as additional analyses.
3.3.5.2
Brain Volumetry
A characteristic feature of AD is neuronal destruction.  Such neuronal loss is 
demonstrated at a macroscopic level by progressive cerebral atrophy, which can be 
tracked on MRI (Fox and Kennedy 2009).  Multiple changes in brain anatomy beyond 
those associated with normal aging have been reported in participants with AD 
(e.g., enlarged ventricles, decreased cortical thickness, decreased total brain volume, 
and hippocampal atrophy), and there is evidence for strong correlations between these 
imaging biomarkers and functional cognitive measures (Mungas et al. 2005; 
Li and Wahlund 2011).  Based on volumetric MRI measurements, the two most 
established markers of disease progression through longitudinal observational studies 
are hippocampal and whole brain atrophy (Fox et al. 2000; Fox et al. 2005; 
Jack et al. 2010), with ventricular expansion being a third and related quantitative marker. 
Therefore, to quantify the effects of gantenerumab on neurodegeneration, whole brain 
volume, ventricular enlargement, and regional brain volume changes will be assessed at 
baseline and following long-term treatment with gantenerumab.  All MRI reads and 
volume measures will be conducted by the central reader.

Gantenerumab —F. Hoffmann-La Roche Ltd
31/Protocol WN41874, Version 2
4.
MATERIALS AND METHODS
4.1
PARTICIPANTS
In Part 1, participants who completed the OLEs of Studies WN25203 or WN28745 were
eligible to participate. Participants who discontinued early from study treatment during 
OLEs of Studies WN25203 or WN28745 (for any reason) were not be eligible in Part 1 
of the study.
In Part 2, participants with AD who have completed the Week 104 visit in Part 1 and 
have not discontinued from study drug per Section 4.6.1, will be given the option to 
continue to participate in Part 2 of the study.
4.1.1
Inclusion Criteria
All participants who completed the OLEs of Studies WN25203 or WN28745 (i.e., latest 
version of protocol in their countries, and did not discontinue study drug early) were 
eligible to participate in Part 1 of the study. 
For women of childbearing potential: agreement to remain abstinent (refrain from 
heterosexual intercourse) or use contraceptive methods that result in a failure rate of 1% 
per year during the treatment period and for at least 16 weeks after the last dose of 
study drug.
A woman is considered to be of childbearing potential if she is postmenarcheal, has not 
reached a postmenopausal state (12 continuous months of amenorrhea with no 
identified cause other than menopause), and has not undergone surgical sterilization 
(removal of ovaries, fallopian tubes, and/or uterus).
Examples of contraceptive methods with a failure rate of 1% per year include bilateral 
tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, 
hormone-releasing intrauterine devices, and copper intrauterine devices.
The reliability of sexual abstinence should be evaluated in relation to the duration of the 
clinical study and the preferred and usual lifestyle of the participant. Periodic abstinence 
(e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are 
not acceptable methods of contraception.
Eligible participants provide written consent signed by them or by the participant’s legally 
authorized representative (LAR) before his or her participation in the study (in 
accordance with applicable laws and Institutional Review Board [IRB]/Ethics Committee 
[EC] policy).
Agreement to not donate blood or blood products for transfusion for the duration of the 
study and for 1 year after final dose of study drug will be needed for all participants.

Gantenerumab —F. Hoffmann-La Roche Ltd
32/Protocol WN41874, Version 2
Availability of a person (referred to as the “caregiver” throughout this protocol) who in 
the investigator’s judgement, has frequent and sufficient contact with the participant.
4.1.2
Exclusion Criteria
Participants who met any of the following criteria will not be eligible: 

Prematurely discontinued from the OLEs of Studies WN25203 or WN28745 or from 
study drug for any reason 

Any medical condition that the investigator or Sponsor determines may jeopardize 
the participant’s safety if he or she continues to receive study treatment

If the participant is unlikely to benefit from gantenerumab therapy, based on disease 
progression or other factors, or if study participation is otherwise not in the 
participant’s best interest, by determination of the investigator or Sponsor

Any investigational treatment other than gantenerumab during or since completion 
of the OLEs of Studies WN25203 or WN28745

Pregnancy

Evidence of disseminated leptomeningeal hemosiderosis (i.e., more than three focal 
leptomeningeal hemosiderosis)

Evidence of intracerebral macrohemorrhage
4.1.3
Eligibility in Part 2

All participants who have completed Week 104 visit in Part 1 of the study and have 
not been discontinued from Part 1 of the study can continue to participate in 
Part 2 of the study

The criteria mentioned in Sections 4.1.1 and 4.1.2 will also be applicable to Part 2 
of the study
4.2
METHOD OF TREATMENT ASSIGNMENT AND BLINDING 
This study is an open-label study, and each participant enrolled will be administered the 
same dose of gantenerumab that was received at the final dosing visit. 
For Part 1, participants who had a dose gap between the last visit from the 
WN25203/WN28745 OLE and this study, depending on the actual duration of the dosing 
gap and their ARIA-E history, may be asked to start with a lower dose, as detailed in 
Appendix 3.
An interactive (voice/web) response system (IxRS) will be used to manage participant, 
enrollment and drug supply. The participant number will be allocated in IxRS and will be 
used in the clinical database and for recording data in the electronic Case Report Form 
(eCRF). The enrollment call to the IxRS should occur on Day 1 after the participant’s 
eligibility (i.e., eligibility criteria) has been confirmed.

Gantenerumab —F. Hoffmann-La Roche Ltd
33/Protocol WN41874, Version 2
4.3
STUDY TREATMENT AND OTHER TREATMENTS RELEVANT 
TO THE STUDY DESIGN
The investigational medicinal product (IMP) for this study is gantenerumab.
At applicable sites, study drug may be administered by a trained nursing professional at 
the participant's home or another suitable location, if the participant has given written 
informed consent to participate in mobile nursing (MN) visits.
4.3.1
Formulation, Packaging, and Handling
Gantenerumab is available in the following drug product formulation:  2 mL vials 
(300 mg/vial) from which drug product needs to be withdrawn via a disposable syringe.  
The study drug can be delivered SC either using multiple syringes, or using a syringe 
pump.  Syringe pumps offer a significant advantage over manual administration because 
they allow delivering higher volumes of the study drug at a defined injection rate. 
All formulations should be stored at 2C8oC and protected from light.  All drug product 
solutions should be brought to room temperature prior to administration to minimize 
discomfort during the injection.
Liquid vials:  Gantenerumab must be prepared for dosing under appropriate aseptic 
conditions as it does not contain antimicrobial preservatives.  The dose solution should 
be used immediately.  If not used immediately, the total storage time of the dose solution 
prior to administration should not exceed 24 hours to limit the risk of microbiological 
growth in case of accidental contamination.  The recommended storage condition for the 
dose solution is 2C8C, but dose solutions may be stored at room temperature for up 
to a maximum of 4 hours. 
Packaging of the study drug will be overseen by the Roche Clinical Trial Supplies 
Department and will bear a label with the identification required by local law, the protocol 
number, study drug identification, and dose.  The packaging and labeling will be in 
accordance with Roche standard and local regulations.  Upon receipt of the 
investigational products at the site, site personnel should check the product for damage 
and verify the proper identity, quantity, and integrity of the study drug.  Site personnel 
should report any deviations or product complaints to the monitor upon discovery. For 
further details, please refer to the Gantenerumab Investigator’s Brochure.
For information on the formulation and handling of gantenerumab, see the pharmacy 
manual and Gantenerumab Investigator’s Brochure.
Refer to the pharmacy manual and other applicable manuals for detailed instructions on 
drug preparation, storage, and administration.
4.3.1.1
Non-Investigational Medicinal Products
Not applicable.  

Gantenerumab —F. Hoffmann-La Roche Ltd
34/Protocol WN41874, Version 2
4.3.1.2
Compliance
Participants who are non-compliant with the study and/or study procedures, defined as 
missing more than three consecutive dose administrations or more than half of the 
dosing visits in a calendar year, because of non-safety-related reasons, may be allowed 
to continue in this study after consulting with the Medical Monitor.
4.3.2
Investigational Medicinal Product Accountability
All IMPs required for completion of this study will be provided by the Sponsor where 
required by local regulations.  The study site (i.e., investigator or other authorized 
personnel [e.g., pharmacist or mobile nurse]) is responsible for maintaining records of 
IMP delivery to the site, IMP inventory at the site, IMP use by each participant, IMP 
distribution to each participant, and disposition or return of unused IMP, thus enabling 
reconciliation of all IMP received and ensuring that participants are provided with doses 
specified by the protocol.  
The study site should follow all instructions included with each shipment of IMP.  The 
study site will acknowledge receipt of IMPs supplied by the Sponsor, using the IxRS to 
confirm the shipment condition and content. Any damaged shipments will be replaced. 
The investigator or designee must confirm that appropriate temperature conditions have 
been maintained during transit, either by time monitoring (shipment arrival date and 
time) or temperature monitoring, for all IMPs received at the site and that any 
discrepancies have been reported and resolved before use of the IMPs.  All IMPs shipped 
to the site must be stored in a secure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions, with 
access limited to the investigator and authorized staff. 
Only participants enrolled in the study may receive the IMP, and only authorized staff 
may supply the IMP, and only authorized staff may administer the IMP.
The IMP will either be disposed of at the study site according to the study site's 
institutional standard operating procedure or be returned to the Sponsor with the 
appropriate documentation. The site's method of destroying Sponsor-supplied IMPs
must be agreed to by the Sponsor. The site must obtain written authorization from the 
Sponsor before any Sponsor-supplied IMP is destroyed, and IMP destruction must be 
documented on the appropriate form.
Accurate records of all IMPs received at, dispensed from, returned to, and disposed of by 
the study site should be recorded on the drug accountability log.
Refer to the pharmacy manual and/or the home administration manual and 
Gantenerumab Investigator's Brochure for information on IMP handling, including 
preparation, storage, and accountability.

Gantenerumab —F. Hoffmann-La Roche Ltd
35/Protocol WN41874, Version 2
4.3.3
Continued Access to Gantenerumab
The Sponsor will offer continued access to Sponsor study drug (gantenerumab) free of 
charge to eligible participants in accordance with the Roche Global Policy on Continued 
Access to Investigational Medicinal Product, as outlined below.
A participant will be eligible to receive Sponsor study drug (gantenerumab) after 
completing the study if all of the following conditions are met:

The participant has a life-threatening or severe medical condition and requires 
continued Sponsor study drug treatment for his or her well-being

There are no appropriate alternative treatments available to the participant

The participant and his or her doctor comply with and satisfy any legal or 
regulatory requirements that apply to them
A participant will not be eligible to receive Sponsor study drug (gantenerumab) after 
completing the study if any of the following conditions are met:

The Sponsor study drug is commercially marketed in the participant's country and 
is reasonably accessible to the participant (e.g., is covered by the participant's 
insurance or wouldn't otherwise create a financial hardship for the participant)

The Sponsor has discontinued development of the drug or data suggest that the 
drug is not effective for AD

The Sponsor has reasonable safety concerns regarding the drug as treatment for 
AD

Provision of the drug is not permitted under the laws and regulations of the 
participant's country

Participant is eligible to enroll in an ongoing gantenerumab open-label study
The Roche Global Policy on Continued Access to Investigational Medicinal Product is 
available at the following website:
http://www.roche.com/policy_continued_access_to_investigational_medicines.pdf
Eligible participants may qualify for continued access or ongoing extension studies as 
outlined above.
4.4
CONCOMITANT THERAPY
Concomitant therapy includes any medication (e.g., prescription drugs, over-the counter 
drugs, vaccines, herbal/homeopathic remedies, nutritional supplements) used by a 
participant 6 months prior to baseline (Day 1) to the study completion visit.  All such 
concomitant medications (including name, dose, administration schedule, start and end 
dates) should be reported to the investigator and recorded on the Concomitant 
Medications Case Report Form (CRF). 

Gantenerumab —F. Hoffmann-La Roche Ltd
36/Protocol WN41874, Version 2
4.4.1
Permitted and Prohibited Therapy
Participants will be permitted to receive any treatment deemed necessary by the
investigator for the management of their disease, with the exception of any other 
disease-modifying drug for AD. For anticoagulant medications, short-term, perioperative 
use of anticoagulant medications will not result in permanent discontinuation from the 
study; however, any such use it is recommended to prospectively seek advice from the 
Medical Monitor and temporary study drug interruption may be required.
4.5
STUDY ASSESSMENTS 
The study assessments are detailed in the following sections.  Please see Appendix 1
for the Schedule of Activities.
At applicable sites, certain study assessments may be performed by a MN professional 
at the participant's home or nursing center to improve access and convenience for 
participants participating in the study. Mobile nursing can be provided for the visits 
where attendance at the study site is not considered necessary (i.e., at visits except for 
Week 24, Week 52, Week 76, Week 104, Week 128, Week 156, Week 180, and 
Week 208). The Sponsor will select a healthcare company that will be responsible for 
providing HN services for participating sites (the MN vendor). The MN vendor is 
responsible for ensuring that all MN professionals are licensed, qualified, and in good 
standing, per applicable regulations, and that appropriate background checks have been 
performed. If the investigator at a participating site determines that MN services are 
appropriate for a participant and the participant gives written informed consent to 
participate in MN visits, the MN network will communicate with the participant and the 
participant’s site. Mobile nursing visits will be scheduled on specified visit days to allow 
relevant assessments to be performed by the MN professional.
4.5.1
Informed Consent Forms and Screening Log
The Sponsor’s sample Informed Consent Form (ICF) (and ancillary sample ICFs such as 
MN ICF, if applicable) will be provided to each site. If applicable, it will be provided in a 
certified translation of the local language. The Sponsor or its designee must review and 
approve any proposed deviations from the Sponsor's sample ICFs or any alternate 
Consent Forms proposed by the site (collectively, the "Consent Forms") before IRB/EC 
submission. The final IRB/EC-approved Consent Forms must be provided to the 
Sponsor for health authority submission purposes according to local requirements.
All participants and caregivers must review, sign, and date the most current 
IRB/EC-approved written ICF(s) before any study-specific assessments or procedures
are performed.
Where approved as per local regulations, the participant’s LAR may sign/co-sign the ICF 
if the participant is no longer able to provide consent.  However, participants will need to 

Gantenerumab —F. Hoffmann-La Roche Ltd
37/Protocol WN41874, Version 2
provide assent that should be documented at the site level.  Participants who do not sign 
the ICF will be discontinued from the study.
An optional substudy may be introduced to obtain post-mortem brain tissue from 
participants for evaluation of the effect of long-term gantenerumab therapy on the brain. 
The opportunity to donate post-mortem brain tissue may be discussed with participants, 
and interested participants would be provided with additional details. Any further 
procedures, with respect to this optional substudy, will be governed by a separate 
Consent Form and separate protocol document.
4.5.2
Medical History, Baseline Conditions, Concomitant Medication, 
and Demographic Data
Medical history and demographic data collected in the OLEs of Studies WN25203 and 
WN28745 will be used in this study and should include clinically significant diseases, 
surgeries, cancer history (including prior cancer therapies and procedures), reproductive 
status smoking history, use of alcohol and drugs of abuse, and all medications (e.g., 
prescription drugs, vaccines, over-the-counter drugs, herbal/homeopathic remedies, 
nutritional supplements) used by the participant within 6 months prior to the baseline visit
(Day 1).  Demographic data will include age, sex, and self-reported race/ethnicity.  
Adverse events, resolved or ongoing, reported in the OLEs of Studies WN25203 and 
WN28745, will be considered as medical history in this study. Medical history and 
demographic data will be automatically transferred to the Study WN41874 eCRF.
4.5.3
Physical Examinations
A physical examination should include an evaluation of the head, eyes, ears, nose, and 
throat, and the cardiovascular, dermatologic, musculoskeletal, respiratory, 
gastrointestinal, and neurologic systems and will be performed as part of the baseline
physical examination.  Any abnormality identified at baseline should be recorded on the 
General Medical History and Baseline Conditions eCRF.
At subsequent visits (for Part 1 and Part 2), per the Schedule of Activities (or as 
clinically indicated), limited, symptom-directed physical examinations should be 
performed.  Change from baseline abnormalities should be recorded in the participant’s 
notes.  New or worsened clinically significant abnormalities should be recorded as 
adverse events on the adverse event eCRF.
In Part 1 of the study, the baseline physical examination results for the participants of
this study will be the same as in the post-treatment follow-up visit in Studies WN25203 
and WN28745 if they occur on the same day or within 4 weeks. The information will be 
recorded in the eCRF at the baseline (Day 1) visit. If the two visits occur more than 
4 weeks apart, the physical examination has to be repeated.

Gantenerumab —F. Hoffmann-La Roche Ltd
38/Protocol WN41874, Version 2
4.5.4
Vital Signs 
Vital signs (systolic and diastolic blood pressure [BP], heart rate, and temperature) will 
be measured as per the Schedule of Activities.  Blood pressure and heart rate should be 
taken when the participant is at rest and should not be measured unless 15 minutes 
have elapsed since the last blood draw.  The same arm should be used for all BP 
measurements.
In Part 1 of the study, the vital signs assessments for the participants in this study at 
baseline will be the same as in the post-treatment follow-up visit in Studies WN25203
and WN28745 if they occur on the same day or within 4 weeks. If the two visits occur 
more than 4 weeks apart, then the assessment will need to be repeated and the 
information will be recorded in the eCRF at the baseline (Day 1) visit.
Vital sign measurements may be performed by a MN professional.
4.5.5
Cognitive Assessments 
The cognitive assessment is the MMSE and will be collected as specified in the 
Schedule of Activities (see Appendix 1). 
The MMSE will be provided as a paper scale and will be entered in designated eCRF.
The MMSE is a set of standardized questions used to evaluate possible cognitive 
impairment and help stage the severity level of this impairment.  The questions target 
six areas:  orientation, registration, attention, short-term recall, language, and 
constructional praxis/visuospatial abilities. The assessment will be completed only by a 
certified MMSE rater.
In Part 1 of the study, the baseline (Day 1) MMSE for the participants will be the same 
as in the post-treatment follow-up visit in Studies WN25203 and WN28745. If the last 
MMSE assessment is completed more than 6 months from the baseline visit, the 
assessment has to be repeated, and will be recorded in the eCRF at the baseline 
(Day 1) visit.
4.5.6
Laboratory Assessments
Samples for the following laboratory tests will be sent to a central laboratory for analysis.  
The baseline laboratory assessment (Part 1 of the study) results for the participants 
participating in this study will be the same as in the post-treatment follow-up visit in
Studies WN25203 and WN28745 if they occur on the same day or within 4 weeks.  If the 
two visits occur more than 4 weeks apart, the laboratory assessments have to be 
repeated.
For sampling procedures, storage conditions, and shipment instructions, see the 
laboratory manual.

Gantenerumab —F. Hoffmann-La Roche Ltd
39/Protocol WN41874, Version 2

Serum Chemistry:  AST/SGOT, ALT/SGPT, alkaline phosphatase, total protein, 
total bilirubin, serum albumin, CPK, sodium, potassium, calcium, BUN, and serum 
creatinine (and creatinine clearance calculated by the central laboratory)

Hematology:  Hemoglobin, hematocrit, RBC (with morphology), WBC, platelet, 
basophil, eosinophil, lymphocyte, monocyte, neutrophil, and WBC–other total counts

Coagulation: Prothrombin time

Urine for Pregnancy:  Urine pregnancy testing will be performed at each dosing
visit (prior to dose administration) and at follow up/early termination/unscheduled
visit for women of childbearing potential (including those who have had a tubal 
ligation), and at the site for any other female participants if required by local
regulations.  If a urine pregnancy test is positive, it must be confirmed by a serum 
pregnancy test at the central laboratory.

Anti-Drug Antibody Sampling:  Plasma samples will be collected to assess the 
possible development of anti-drug antibodies (ADAs) in all participants as noted in 
the Schedule of Activities (see Appendix 1).  Unused sample material may also be 
used for the purposes of current ADA assay improvement.

PK samples: Collection of a PK plasma sample at the time of the ADA sample 
collection is required for the ADA assessment. Plasma samples will be collected to 
evaluate the plasma levels of gantenerumab for ADA assessment as per Schedule 
of Activities.

Biomarker Samples: Plasma samples will be collected at baseline (Day 1) before 
dosing, once yearly, at the end of the study, and at early termination visit (for 
details see Schedule of Activities [Appendix 1]) for exploratory research on 
biomarkers and biomarker assay development
Biomarker research may include, but will not be limited to amyloid assessments.
Unless the participant gives specific consent for his or her leftover samples to be stored 
for optional exploratory research (see Section 4.5.10), biological samples will be 
destroyed no later than the time of completion of the final Clinical Study Report, with the 
following exceptions:

PK and ADA samples will be destroyed no later than 5 years after the final Clinical 
Study Report has been completed. 

Biomarker plasma samples collected for biomarker research and biomarker assay 
development will be destroyed no later than 5 years after the final Clinical Study 
Report has been completed. However, the storage period will be in accordance with 
the IRB/EC-approved ICF and applicable laws (e.g., health authority requirements).
When a participant withdraws from the study, samples collected prior to the date of 
withdrawal may still be analyzed, unless the participant specifically requests that the 
samples be destroyed or local laws require destruction of the samples.  However, if 
samples have been tested prior to withdrawal, results from those tests will remain as 
part of the overall research data.

Gantenerumab —F. Hoffmann-La Roche Ltd
40/Protocol WN41874, Version 2
Data arising from sample analysis will be subject to the confidentiality standards 
described in Section 8.4.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
participants unless required by law.  The aggregate results of any conducted research 
will be available in accordance with the effective Sponsor policy on study data 
publication.
4.5.7
Electrocardiograms
After 5 minutes in a supine position, a single 12-lead ECG read will be performed at 
baseline and any time during the study if deemed necessary by the investigator. Body 
position should be consistently maintained for each ECG evaluation to prevent changes 
in heart rate.  Environmental distractions (e.g., television, radio, conversation) should be 
avoided during the pre-ECG resting period and during ECG recording.  
All ECGs will be performed using a local ECG device.  ECGs for each participant should 
be only obtained from the same machine, where possible.  On visits where ECGs and 
other laboratory assessments are performed, ECGs should be performed prior to any 
blood draws, and brain MRI scans. ECG characteristics, including heart rate, QRS 
duration, and RR, PR, and QT intervals, will be evaluated by the Principal Investigator 
(PI) and ensure there are no clear alerts for quality or clinical issues and then sign and 
date the outputs.
Paper copies of ECG tracings will be kept as part of the participant's permanent study 
file at the site.
4.5.8
Columbia-Suicide Severity Rating Scale
The C-SSRS (http://www.cssrs.columbia.edu) is an assessment tool used to assess any 
new instances of suicidality (C-SSRS >6 months since last visit). The structured 
interview prompts recollection of suicidal ideation, including the intensity of the ideation, 
behavior, and attempts with actual or potential lethality.  The C-SSRS since the last visit 
will be collected at visits as indicated in the Schedule of Activities (see Appendix 1).  The 
assessment will be completed by a certified C-SSRS rater after he or she interviews the 
participant and the participant’s caregiver during the study visit.
The baseline (Day 1) C-SSRS for the participants participating in this study will be the 
same as in the post- treatment follow-up visit in Studies WN25203 and WN28745. If the 
last C-SSRS assessment was completed more than 6 months from the baseline visit, the 
assessment has to be repeated, this will be recorded in the eCRF at the baseline 
(Day 1) visit.

Gantenerumab —F. Hoffmann-La Roche Ltd
41/Protocol WN41874, Version 2
4.5.9
Brain Magnetic Resonance Imaging
The MRI should be performed using 1.5-T or 3.0-T scanners, and the same scanner is 
strongly preferred for an individual participant for the full duration of the study. Only 
scanners approved for use in the study should be used. MRI will be conducted at 
baseline for safety monitoring prior to dosing and for structural brain volumes measures.  
Magnetic resonance imaging will be used during the study to help assess safety such as 
the occurrence of microbleeds or signs potentially indicative of inflammation or ARIA-E.  
Additional unscheduled MRI scans may be utilized to better understand relevant CNS
related-adverse events (such as increased confusion) or to follow a sign that emerges at 
a scheduled scan; contrast agent may be used in such a case of follow-up if 
administration of contrast agent is considered safe for the participant according to local 
standards.  
MRI scans will include the following sequences:

3D T1-weighted gradient recalled echo (GRE) scans

T2*-weighted GRE scans

T2-weighted fluid-attenuated inversion recovery (FLAIR) scans
The MRI will take approximately 30 minutes to complete. 
The MRI scans will be reviewed by a central MRI core laboratory, which will perform the 
diagnostic reads and assessment of MRI outcome measures.  Magnetic resonance
imaging scans should preferably be transferred to the central MRI core laboratory 
electronically.  Data transfer from individual study sites to the central MRI core laboratory 
may take up to 710 days, if not done electronically.  Upon receipt of the MRI scans 
from the study sites, the central MRI core laboratory will provide the diagnostic reads.  
MRI results must be made available to investigators prior to the next dosing visit.
The MRI facility qualification and scan quality control will be performed by the central 
MRI core laboratory. 
The MRI scan performed for the follow-up visit in Studies WN25203 and WN28745 will 
be used as baseline scan in this study, where possible.  In case there might be a gap 
between follow-up visit from OLEs of WN25203/WN28745 and the first dose in this study
of more than six months MRI has to be repeated. 
Additional instructions regarding the procedures for MRI facility qualification and MRI 
scan acquisition and transmittal to the central reading facility can be found in the 
MRI Manual.

Gantenerumab —F. Hoffmann-La Roche Ltd
42/Protocol WN41874, Version 2
4.5.9.1
Healthy Volunteer Magnetic Resonance Imaging Scans for Site 
Qualification
Investigational sites that have not experienced a discontinuation in MRI scheduling from 
the previous OLE Studies WN25203 and WN28745 may not require MRI scan 
requalification. This will be determined by the MRI vendor on a case by case basis.
If deemed necessary, as part of site qualification, one to two healthy volunteers 
(preferably two) at each site should be recruited and scanned using the same machine 
and the same sequences to be used for site qualification before any participant is 
scanned in this study.  The choice of healthy volunteers is at the discretion of the 
Principal Investigator and/or the imaging center, and the volunteer must provide written 
consent to take part in the scanning calibration.  Volunteers must not have any 
contraindications for MRI scanning (evaluation as per local procedures at the imaging 
site), and they will not be enrolled in the study or undergo any other assessments as part 
of the study.  If volunteer scans are acquired, then they will be reviewed for suitable 
image quality and used for qualitative comparison with additional scans with the same 
volunteer acquired after certain events as follows:  at the time of a major upgrade to the 
site’s scanner, or any other event deemed significant enough to affect image quality.  
This procedure will help ensure consistency in scanning quality over the duration of the 
study.  Two volunteers are ideal in case one volunteer is no longer readily available for 
test scanning.
4.5.10
Optional Samples for Research Biosample Repository
4.5.10.1
Overview of the Research Biosample Repository
The Research Biosample Repository (RBR) is a centrally administered group of facilities
used for the long-term storage of human biological specimens, including body fluids,
solid tissues, and derivatives thereof (e.g., DNA, RNA, proteins, peptides). The
collection, storage, and analysis of RBR samples will facilitate the rational design of new
pharmaceutical agents and the development of diagnostic tests, which may allow for
individualized drug therapy for participants in the future. Specimens for the RBR will be 
collected from retaining the residual samples remaining after the protocol-specified 
analysis has been performed on protocol-specified mandatory biomarker samples. 
Research Biosample Repository samples will be analyzed to achieve one or more of the 
following objectives:

To study the association of biomarkers with efficacy or disease progression

To identify safety biomarkers that are associated with susceptibility to developing
adverse events or can lead to improved adverse event monitoring or investigation

To increase knowledge and understanding of disease biology and drug safety

To study drug response, including drug effects and the processes of drug absorption
and disposition

To develop biomarker or diagnostic assays and establish the performance
characteristics of these assays

Gantenerumab —F. Hoffmann-La Roche Ltd
43/Protocol WN41874, Version 2
4.5.10.2
Approval by the Institutional Review Board or Ethics 
Committee
Collection, storage, and analysis of RBR samples is contingent upon the review and 
approval of the exploratory research and the RBR portion of the ICF by each site's 
IRB/EC and, if applicable, an appropriate regulatory body.  If a site has not been granted 
approval for RBR sampling, this section of the protocol (Section 4.5.10) will not be 
applicable at that site.
4.5.10.3
Sample Collection
Leftover plasma biomarker samples will be stored in the RBR and used for research 
purposes, including, but not limited to, research on biomarkers related to gantenerumab, 
diseases, or drug safety.
Data generated from RBR samples will be analyzed in the context of this study but may 
also be explored in aggregate with data from other studies.  The availability of a larger 
dataset will assist in identification and characterization of important biomarkers and 
pathways to support future drug development.
See the laboratory manual for sampling procedures, storage conditions, and shipment 
instructions.  
Research Biosample Repository samples are to be stored until they are no longer 
needed or until they are exhausted.  However, the RBR storage period will be in 
accordance with the IRB/EC-approved ICF and applicable laws (e.g., health authority 
requirements).
4.5.10.4
Confidentiality
Research Biosample Repository samples and associated data will be labeled with a 
unique participant identification number.
Participant medical information associated with RBR samples is confidential and may be 
disclosed to third parties only as permitted by the ICF (or separate authorization for use 
and disclosure of personal health information) signed by the participant, unless permitted 
or required by law.
Given the complexity and exploratory nature of the analyses of RBR samples, data 
derived from these analyses will generally not be provided to study investigators or 
participants unless required by law.  The aggregate results of any conducted research 
will be available in accordance with the effective Sponsor policy on study data 
publication.
Data generated from RBR samples must be available for inspection upon request by 
representatives of national and local health authorities, and Sponsor monitors, 
representatives, and collaborators, as appropriate.

Gantenerumab —F. Hoffmann-La Roche Ltd
44/Protocol WN41874, Version 2
Any inventions and resulting patents, improvements, and/or know-how originating from 
the use of the RBR data will become and remain the exclusive and unburdened property 
of the Sponsor, except where agreed otherwise.
4.5.10.5
Consent to Participate in the Research Biosample Repository
The ICF will contain a separate section that addresses participation in the RBR.  The 
investigator or authorized designee will explain to each participant the objectives, 
methods, and potential hazards of participation in the RBR.  Participants will be told that 
they are free to refuse to participate and may withdraw their consent at any time and for 
any reason during the storage period.  A separate, specific signature will be required to 
document a participant's agreement to provide optional RBR samples.  Participants who 
decline to participate will not provide a separate signature.
The investigator should document whether or not the participant has given consent to 
participate and (if applicable) the date(s) of consent, by completing the RBR Research 
Sample Informed Consent eCRF.
In the event of an RBR participant's death or loss of competence, the participant's 
samples and data will continue to be used as part of the RBR research.
4.5.10.6
Withdrawal from the Research Biosample Repository
Participants who give consent to provide RBR samples have the right to withdraw their 
consent at any time for any reason.  After withdrawal of consent, any remaining samples 
will be destroyed or will no longer be linked to the participant.  However, if RBR samples 
have been tested prior to withdrawal of consent, results from those tests will remain as 
part of the overall research data.  If a participant wishes to withdraw consent to the 
testing of his or her RBR samples during the study, the investigator must inform the 
Medical Monitor in writing of the participant's wishes through use of the appropriate RBR 
Subject Withdrawal Form and must enter the date of withdrawal on the RBR Research 
Sample Withdrawal of Informed Consent eCRF.  If a participant wishes to withdraw 
consent to the testing of his or her RBR samples after closure of the site, the investigator 
must inform the Sponsor by emailing the study number and participant number to the 
following email address:
global rcr-withdrawal@roche.com
A participant's withdrawal from this study does not, by itself, constitute withdrawal of 
consent for testing of RBR samples.  Likewise, a participant's withdrawal of consent for 
testing of RBR samples does not constitute withdrawal from this study.
4.5.10.7
Monitoring and Oversight
Research Biosample Repository samples will be tracked in a manner consistent with 
Good Clinical Practice (GCP) by a quality-controlled, auditable, and appropriately 
validated laboratory information management system, to ensure compliance with data 
confidentiality as well as adherence to authorized use of samples as specified in this 

Gantenerumab —F. Hoffmann-La Roche Ltd
45/Protocol WN41874, Version 2
protocol and in the ICF.  Sponsor monitors and auditors will have direct access to 
appropriate parts of records relating to participant participation in the RBR for the 
purposes of verifying the data provided to the Sponsor.  The site will permit monitoring, 
audits, IRB/EC review, and health authority inspections by providing direct access to 
source data and documents related to the RBR samples.
4.5.11
Unscheduled Assessments 
Assessments at unscheduled visits should be determined by the investigator based on 
clinical relevance and appropriateness to the cause of the unscheduled visit. The 
Schedule of Activities in Appendix 1 allows for all assessments to be performed at 
unscheduled visits.
4.6
TREATMENT, PARTICIPANT, STUDY, AND SITE 
DISCONTINUATION
4.6.1
Study Treatment Discontinuation
Participants must discontinue study treatment if they experience any of the following:

Any medical condition that the investigator or Sponsor determines may jeopardize 
the participant’s safety if he or she continues to receive study treatment

Investigator or Sponsor determination that treatment discontinuation is in the best 
interest of the participant

Pregnancy

Upon evidence of any disseminated leptomeningeal hemosiderosis (i.e., more than 
three focal leptomeningeal hemosiderosis)

Upon evidence of intracerebral macrohemorrhage
All participants who withdraw from treatment will be asked to return 4 weeks after last
dose to complete the early termination visit assessments. 
The primary reason for study treatment discontinuation should be documented on the 
appropriate eCRF.  
4.6.2
Participant Discontinuation
Participants have the right to voluntarily withdraw from the study at any time for any 
reason.  In addition, the investigator has the right to withdraw a participant from the 
study at any time.  Reasons for withdrawal from the study may include, but are not 
limited to, the following:

Participant withdrawal of consent at any time

Study termination or site closure

Any medical condition that the investigator or Sponsor determines may jeopardize 
the participant’s safety if he or she continues in the study

Investigator or Sponsor determines it is in the best interest of the participant

Gantenerumab —F. Hoffmann-La Roche Ltd
46/Protocol WN41874, Version 2
All participants who discontinue from the study early will be asked to return 4 weeks after
last dose to complete the early termination visit. 
Participants should be informed of circumstances under which their participation may be 
terminated by the investigator without the participant’s consent.  Any administrative or 
other reasons for withdrawal must be explained to the participant.
Every effort should be made to obtain information on participants who withdraw from the 
study.  The primary reason for withdrawal from the study should be documented on the 
appropriate eCRF.  However, participants will not be followed for any reason after 
consent has been withdrawn.  
4.6.3
Study Discontinuation
The Sponsor has the right to terminate this study at any time.  Reasons for terminating 
the study may include, but are not limited to, the following:

The incidence or severity of adverse events in this or other studies indicates a 
potential health hazard to participants

Participant enrollment is unsatisfactory

Sponsor determines it is the best interest of the participants
The Sponsor will notify the investigator if the Sponsor decides to discontinue the study.  
4.6.4
Site Discontinuation
The Sponsor has the right to close a site at any time.  Reasons for closing a site may 
include, but are not limited to, the following:

High drop-out rate

Poor protocol adherence

Inaccurate or incomplete data recording

Non-compliance with the International Conference for Harmonization of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline 
for GCP

No study activity (i.e., all participants have completed the study and all obligations 
have been fulfilled)
5.
ASSESSMENT OF SAFETY
5.1
SAFETY PLAN
Gantenerumab is not yet approved, and clinical development is ongoing.  The safety 
plan for participants in this study is based on clinical experience with gantenerumab in 
completed and ongoing studies.  The identified risks for gantenerumab are outlined 
below.  Please refer to the gantenerumab IB for a complete summary of safety 
information.

Gantenerumab —F. Hoffmann-La Roche Ltd
47/Protocol WN41874, Version 2
Several measures will be taken to ensure the safety of participants in this study.  
Eligibility criteria have been designed to exclude participants at higher risk for imaging
related abnormalities.  Participants will undergo safety monitoring during the study, 
including assessment of the nature, frequency, and severity of adverse events.  In 
addition, guidelines for managing adverse events, including criteria for dosage 
modification and treatment interruption or discontinuation, are provided below.
Participants should be observed for a minimum one-hour post IMP administration. 
Rescue medications to treat anaphylactic and anaphylactoid reactions must be available 
at the site or at the dosing location for MN visits.  Participants and their study 
partners will be alerted to watch for signs of anaphylactic and anaphylactoid reactions 
and to contact the study center as soon as possible if any such signs are noted (refer to 
the pharmacy manual).
5.1.1
Risks Associated with Gantenerumab
5.1.1.1
Amyloid-Related Imaging Abnormalities
Amyloid-related imaging abnormality is the most significant adverse event reported 
with therapies against aggregated forms of A.  These findings are dose-, time-, and 
APOE 4 allele-dependent (Piazza and Winblad 2016).
The mechanism underlying the development of ARIA-E and ARIA-H during anti-
amyloid treatment is unknown.  Because antibodies target removal of Afrom both the 
parenchyma and cerebral vasculature, vessels with preexisting amyloid vascular 
pathology might become transiently more susceptible to leakage of vascular contents.  
This pathology results in ARIA-E if the leakage consists of proteinaceous fluid and in 
ARIA-H if the leakage consists of blood products (Sperling et al. 2012).
Thus, an anti-Atherapy that effectively maintains vascular -amyloid clearance 
would allow vascular remodeling and may, with time, decrease the risk of such 
extravasation events (Sperling et al. 2012).  This is consistent with experience in 
previous and ongoing studies and with reported data from the long-term extension 
study of aducanumab treatment (Viglietta et al. 2016).
In this study, an MRI scan documenting the absence of disseminated leptomeningeal 
hemosiderosis will be required prior to first gantenerumab dose. If ARIA findings 
occur, more intense MRI monitoring, dose adjustments, temporary dose holding, or 
permanent discontinuation will be implemented according to an ARIA-related 
dose-adjustment plan, described in Section 5.1.2.  Safety findings (including individual 
participant and aggregate data) will be reviewed on a regular basis by the Roche 
Internal Monitoring Committee (IMC).
To date, clinical experience with gantenerumab has shown that ARIA events are time,
dose, and APOE 4 dependent.  ARIA events are manageable with MRI monitoring and 

Gantenerumab —F. Hoffmann-La Roche Ltd
48/Protocol WN41874, Version 2
dose intervention algorithms.  In addition, in case of clinical symptoms associated with 
ARIA-E, the use of IV glucocorticosteroids may be considered.
Rules for management of participants who develop ARIA-E or ARIA-H are provided in
Appendix 2.
5.1.1.2
Injection-Site Reactions
Gantenerumab may cause a reaction when given as an SC injection.  In studies with 
gantenerumab, the most common adverse events occurring more frequently with 
gantenerumab than with placebo were local ISRs, such as injection-site erythema.  The 
majority of events were of mild intensity and resolved without treatment.
Detailed information on the characteristic signs and symptoms of ISRs (e.g., erythema, 
pruritus) will be recorded on the dedicated eCRF page.
5.1.1.3
Immunogenicity
As with administration of any exogenous protein, a potential exists for the development 
of ADAs which can be neutralizing and/or sensitizing, producing the potential for 
febrile or allergic reactions, including anaphylaxis. The immunogenic risk of 
gantenerumab is considered low given it is a fully human antibody.
Anti-drug antibodies against gantenerumab were assessed in Studies BP29113, 
BP30042, WP39322, WP22461, WP27951, WP40052, NN19866, JP22431, WN25203,
and WN28745 using a validated two-step bridging ELISA.  
Of the 1312 clinical trial participants who have received gantenerumab at any of the 
doses investigated in these studies and had a post-baseline ADA assay result, 
68 participants (5.2%) showed treatment-emergent (induced or enhanced) ADA to 
gantenerumab.  The percent of participants with treatment-induced ADAs was 4.8% in 
the gantenerumab-treated group. A total of 478 participants received placebo and had 
a post-baseline ADA assay result of which 21 participants (4.4%) showed 
treatment-emergent ADA.  Overall, 2.3% in the placebo group had treatment-induced 
ADAs. The majority of positive ADA results were below a titer (sample dilution factor) of 
100.
In general, gantenerumab plasma concentration levels were similar between 
ADA-negative and ADA-positive participants. A correlation between ADA response and 
decreased gantenerumab plasma concentrations was only reported in two ADA-positive 
participants in the Japanese MAD Study JP22431.
There are no clinical findings indicative of an immunogenic response to gantenerumab.

Gantenerumab —F. Hoffmann-La Roche Ltd
49/Protocol WN41874, Version 2
5.1.2
Management of Participants Who Experience Selected 
Adverse Events
For Part 1 of the study, each participant continued to receive SC gantenerumab Q4W at 
the dose they received in the qualifying study (OLE part of Studies WN25203 or 
WN28745) and will undergo a brain MRI examination as per Schedule of Activities, with 
the following exception: Participants who experienced a dosing gap of more than 
16 weeks for any reason between the last gantenerumab dose in the qualifying study 
and first gantenerumab dose in this study may, depending upon whether they previously 
experienced an ARIA-E event, start dosing at a lower dose and undergo an up-titration 
step (see Appendix 3). A brain MRI examination will be required prior to the dose 
increase (pre-up-titration MRI scan) and then according to the Schedule of Activities
once the target dose is reached.  The pre-up-titration MRI scan will determine eligibility 
for the next dose, as described in Appendix 2.
In the case that a participant has at the baseline (Day 1) visit an ARIA-E that is ongoing 
since the qualifying study, there will be a continuity of ARIA management between the 
two studies, and ARIA management rules as described in Appendix 2 will apply
For ARIA MRI findings detected during the study (Part 1 and Part 2), the dose 
adjustment and discontinuation rules described in Appendix 2 will apply.
The IMC will review the nature, incidence, severity, and timing of ARIA findings and may 
recommend adjustment of dosing regimen and/or ARIA management for the overall 
study population or for a specific APOE ε4 genotype.
5.2
SAFETY PARAMETERS AND DEFINITIONS
Safety assessments will consist of monitoring and recording adverse events, including 
serious adverse events and adverse events of special interest, performing 
protocol-specified safety laboratory assessments, measuring protocol-specified vital 
signs, and conducting other protocol-specified tests that are deemed critical to the safety 
evaluation of the study.
Certain types of events require immediate reporting to the Sponsor, as outlined in
Section 5.4.
5.2.1
Adverse Events
According to the ICH guideline for GCP, an adverse event is any untoward medical 
occurrence in a clinical investigation subject administered a pharmaceutical product, 
regardless of causal attribution.  An adverse event can therefore be any of the following:

Any unfavorable and unintended sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal product, 
whether or not considered related to the medicinal product

Gantenerumab —F. Hoffmann-La Roche Ltd
50/Protocol WN41874, Version 2

Any new disease or exacerbation of an existing disease (a worsening in the 
character, frequency, or severity of a known condition), except as described in 
Section 5.3.5.11

Recurrence of an intermittent medical condition (e.g., headache) not present at 
baseline

Any deterioration in a laboratory value or other clinical test (e.g., ECG, X-ray) that is 
associated with symptoms or leads to a change in study treatment or concomitant 
treatment or discontinuation from study drug

Adverse events that are related to a protocol-mandated intervention, including those 
that occur prior to assignment of study treatment 
5.2.2
Serious Adverse Events (Immediately Reportable to 
the Sponsor)
A serious adverse event is any adverse event that meets any of the following criteria:

Is fatal (i.e., the adverse event actually causes or leads to death)

Is life threatening (i.e., the adverse event, in the view of the investigator, places the 
participant at immediate risk of death)
– This does not include any adverse event that had it occurred in a more severe 
form or was allowed to continue might have caused death

Requires or prolongs inpatient hospitalization (see Section 5.3.5.12)

Results in persistent or significant disability/incapacity (i.e., the adverse event
results in substantial disruption of the participant’s ability to conduct normal life 
functions)

Is a congenital anomaly/birth defect in a neonate/infant born to a mother exposed to 
study drug

Is a significant medical event in the investigator's judgment (e.g., may jeopardize the 
participant or may require medical/surgical intervention to prevent one of the 
outcomes listed above)
The terms "severe" and "serious" are not synonymous.  Severity refers to the intensity of 
an adverse event (e.g., rated as mild, moderate, or severe; the event itself may be of 
relatively minor medical significance such as severe headache without any further 
findings).
Severity and seriousness need to be independently assessed for each adverse event
recorded on the eCRF.
Serious adverse events are required to be reported by the investigator to the Sponsor 
immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for 
reporting instructions).

Gantenerumab —F. Hoffmann-La Roche Ltd
51/Protocol WN41874, Version 2
5.2.3
Adverse Events of Special Interest (Immediately Reportable to 
the Sponsor)
Adverse events of special interest are required to be reported by the investigator to the 
Sponsor immediately (i.e., no more than 24 hours after learning of the event; see 
Section 5.4.2 for reporting instructions).  Adverse events of special interest for this study 
include the following:

Cases of potential drug-induced liver injury that include an elevated ALT or AST in 
combination with either an elevated bilirubin or clinical jaundice, without evidence of 
another liver or biliary disorder as defined by Hay’s Law (see Section 5.3.5.8)

Suspected transmission of an infectious agent by the study drug, as defined below:
–
Any organism, virus, or infectious particle (e.g., prion protein transmitting 
transmissible spongiform encephalopathy), pathogenic or non-pathogenic, is 
considered an infectious agent.  A transmission of an infectious agent may be 
suspected from clinical symptoms or laboratory findings that indicate an 
infection in a participant exposed to a medicinal product.  This term applies only 
when a contamination of the study drug is suspected
5.2.4
Selected Adverse Events 
Data on associated symptoms and safety MRI scans will be collected for the following 
selected adverse events:

ARIA-E:  ARIAs suggestive of vasogenic edema and sulcal effusions

ARIA-H:  ARIAs suggestive of microhemorrhages and/or hemosiderin deposits
Please refer also to Section 5.3.5.1 for further details how to report ARIA events.
5.3
METHODS AND TIMING FOR CAPTURING AND ASSESSING 
SAFETY PARAMETERS
The investigator is responsible for ensuring that all adverse events (see Section 5.2.1 for 
definition) are recorded on the adverse event eCRF and reported to the Sponsor in 
accordance with instructions provided in this section and in Sections 5.45.6. The 
investigator is also responsible for reporting medical device complaints (see 
Section 5.4.4)
For each adverse event recorded on the adverse event eCRF, the investigator will make 
an assessment of seriousness (see Section 5.2.2 for seriousness criteria), severity (see 
Section 5.3.3), and causality (see Section 5.3.4).
5.3.1
Adverse Event Reporting Period
Investigators will seek information on adverse events at each participant contact.  All 
adverse events, whether reported by the participant/caregiver or noted by study 
personnel, will be recorded in the participant’s medical record and on the adverse event
eCRF.

Gantenerumab —F. Hoffmann-La Roche Ltd
52/Protocol WN41874, Version 2
After informed consent has been obtained but prior to the first administration of study 
drug in this study, only serious adverse events caused by a protocol-mandated 
intervention (e.g., invasive procedures, discontinuation of medications) should be 
reported (see Section 5.4.2 for instructions for reporting serious adverse events). 
After the first dose of study drug in this study, all adverse events will be reported until the 
participant’s last visit (including long-term follow-up visit).
Instructions for reporting adverse events that occur after the adverse event reporting 
period are provided in Section 5.6.
5.3.2
Eliciting Adverse Event Information
A consistent methodology of non-directive questioning should be adopted for eliciting 
adverse event information at all participant evaluation timepoints.  Examples of 
non-directive questions include the following:

"How have you felt since your last clinic visit?"

"Have you had any new or changed health problems since you were last here?" 
5.3.3
Assessment of Severity of Adverse Events
Table 2 provides guidance for assessing adverse event severity.
Table 2
Adverse Event Severity Grading Scale
Severity
Description
Mild
Discomfort noticed, but no disruption of normal daily activity
Moderate
Discomfort sufficient to reduce or affect normal daily activity
Severe
Incapacitating with inability to work or to perform normal daily activity
Note:  Regardless of severity, some events may also meet seriousness criteria.  
Refer to definition of a serious adverse event (see Section 5.2.2).
5.3.4
Assessment of Causality of Adverse Events
Investigators should use their knowledge of the participant, the circumstances 
surrounding the event, and an evaluation of any potential alternative causes to 
determine whether an adverse event is considered to be related to the study drug, 
indicating "yes" or "no" accordingly.  The following guidance should be taken into 
consideration:

Temporal relationship of event onset to the initiation of study drug

Course of the event, with special consideration of the effects of dose reduction, 
discontinuation of study drug, or reintroduction of study drug (as applicable)

Known association of the event with the study drug or with similar treatments

Known association of the event with the disease under study

Gantenerumab —F. Hoffmann-La Roche Ltd
53/Protocol WN41874, Version 2

Presence of risk factors in the participant or use of concomitant medications known 
to increase the occurrence of the event

Presence of non-treatment-related factors that are known to be associated with the 
occurrence of the event
5.3.5
Procedures for Recording Adverse Events
Investigators should use correct medical terminology/concepts when recording adverse 
events on the adverse event eCRF.  Avoid colloquialisms and abbreviations.
Only one adverse event term should be recorded in the event field on the adverse event
eCRF.
5.3.5.1
Amyloid-related Imaging Abnormality Findings
Not every ARIA finding in MRI qualifies as an adverse event.  An ARIA finding must be 
reported as an adverse event if it meets any of the following criteria:

ARIA-E which is symptomatic (i.e., accompanied by CNS symptoms), and/or

ARIA that results in a change in study treatment (e.g., dosage modification, 
treatment interruption, or treatment discontinuation), and/or

Is otherwise clinically significant in the investigator’s judgment
Any accompanying symptoms should also be captured as separate adverse events.
It is the investigator’s responsibility to review all ARIA findings.  
Observations of the same clinically significant ARIA finding should only be recorded 
once on the adverse event eCRF (see Section 5.3.5.5 for details on recording persistent 
adverse events).
5.3.5.2
Injection Reactions 
Injection reactions (local and systemic) are defined as adverse events that occur during 
or within 24 hours after study drug administration and that are judged to be related to the 
study drug injection.
For local reactions, the diagnosis of ISR should be captured on the adverse event eCRF 
and associated signs and symptoms (e.g., erythema at injection site) should be recorded 
on the dedicated injection-site reaction eCRF. 
Systemic reactions should be recorded as a single diagnosis on the adverse event
eCRF (e.g., anaphylactic reaction).  If possible, avoid ambiguous terms such as 
"systemic reaction." 
5.3.5.3
Diagnosis vs. Signs and Symptoms
A diagnosis (if known) should be recorded on the adverse event eCRF rather than 
individual signs and symptoms (e.g., record only liver failure or hepatitis rather than 

Gantenerumab —F. Hoffmann-La Roche Ltd
54/Protocol WN41874, Version 2
jaundice, asterixis, and elevated transaminases).  However, if a constellation of signs 
and/or symptoms cannot be medically characterized as a single diagnosis or syndrome 
at the time of reporting, each individual event should be recorded on the adverse event
eCRF.  If a diagnosis is subsequently established, all previously reported adverse events
based on signs and symptoms should be nullified and replaced by one adverse event
report based on the single diagnosis, with a starting date that corresponds to the starting 
date of the first symptom of the eventual diagnosis.
5.3.5.4
Adverse Events That Are Secondary to Other Events
In general, adverse events that are secondary to other events (e.g., cascade events or 
clinical sequelae) should be identified by their primary cause, with the exception of 
severe or serious secondary events.  A medically significant secondary adverse event
that is separated in time from the initiating event should be recorded as an independent 
event on the adverse event eCRF.  For example if:

Vomiting results in mild dehydration with no additional treatment in a healthy adult, 
only vomiting should be reported on the eCRF

Vomiting results in severe dehydration, both events should be reported separately 
on the eCRF

A severe gastrointestinal hemorrhage leads to renal failure, both events should be 
reported separately on the eCRF

Dizziness leads to a fall and consequent fracture, all three events should be 
reported separately on the eCRF

Neutropenia is accompanied by an infection, both events should be reported 
separately on the eCRF
All adverse events should be recorded separately on the adverse event eCRF if it is 
unclear as to whether the events are associated.
5.3.5.5
Persistent or Recurrent Adverse Events
A persistent adverse event is one that extends continuously, without resolution, between 
participant evaluation timepoints.  Such events should only be recorded once on the 
adverse event eCRF.  The initial severity (intensity or grade) of the event will be 
recorded at the time the event is first reported.  If a persistent adverse event becomes 
more severe, the most extreme severity should also be recorded on the adverse event
eCRF.  If the event becomes serious, it should be reported to the Sponsor immediately 
(i.e., no more than 24 hours after learning that the event became serious; see 
Section 5.4.2 for reporting instructions).  The adverse event eCRF should be updated 
by changing the event from "non-serious" to "serious," providing the date that the event 
became serious, and completing all data fields related to serious adverse events.
A recurrent adverse event is one that resolves between participant evaluation timepoints 
and subsequently recurs.  Each recurrence of an adverse event should be recorded as a 
separate event on the adverse event eCRF.

Gantenerumab —F. Hoffmann-La Roche Ltd
55/Protocol WN41874, Version 2
5.3.5.6
Abnormal Laboratory Values
Not every laboratory abnormality qualifies as an adverse event. A laboratory test result 
must be reported as an adverse event if it meets any of the following criteria:

Is accompanied by clinical symptoms

Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)

Results in a medical intervention (e.g., potassium supplementation for hypokalemia) 
or a change in concomitant therapy

Is clinically significant in the investigator’s judgment 
It is the investigator’s responsibility to review all laboratory findings.  Medical and 
scientific judgment should be exercised in deciding whether an isolated laboratory 
abnormality should be classified as an adverse event.
If a clinically significant laboratory abnormality is a sign of a disease or syndrome 
(e.g., alkaline phosphatase and bilirubin 5upper limit of normal [ULN] associated with 
cholestasis), only the diagnosis (i.e., cholestasis) should be recorded on the adverse 
event eCRF.
If a clinically significant laboratory abnormality is not a sign of a disease or syndrome, 
the abnormality itself should be recorded on the adverse event eCRF, along with a 
descriptor indicating whether the test result is above or below the normal range (e.g.,
"elevated potassium," as opposed to "abnormal potassium").  If the laboratory 
abnormality can be characterized by a precise clinical term per standard definitions, the 
clinical term should be recorded as the adverse event.  For example, an elevated serum 
potassium level of 7.0 mEq/L should be recorded as "hyperkalemia".
Observations of the same clinically significant laboratory abnormality from visit to visit 
should only be recorded once on the adverse event eCRF (see Section 5.3.5.5 for 
details on recording persistent adverse events).
5.3.5.7
Abnormal Vital Sign Values
Not every vital sign abnormality qualifies as an adverse event.  A vital sign result must 
be reported as an adverse event if it meets any of the following criteria:

Is accompanied by clinical symptoms

Results in a change in study treatment (e.g., dosage modification, treatment 
interruption, or treatment discontinuation)

Results in a medical intervention or a change in concomitant therapy

Is clinically significant in the investigator’s judgment 

Gantenerumab —F. Hoffmann-La Roche Ltd
56/Protocol WN41874, Version 2
It is the investigator’s responsibility to review all vital sign findings.  Medical and scientific 
judgment should be exercised in deciding whether an isolated vital sign abnormality 
should be classified as an adverse event.
If a clinically significant vital sign abnormality is a sign of a disease or syndrome 
(e.g., high BP), only the diagnosis (i.e., hypertension) should be recorded on the adverse 
event eCRF.
Observations of the same clinically significant vital sign abnormality from visit to visit 
should only be recorded once on the adverse event eCRF (see Section 5.3.5.5 for 
details on recording persistent adverse events).
5.3.5.8
Abnormal Liver Function Tests
The finding of an elevated ALT or AST (3ULN) in combination with either an elevated 
total bilirubin (2ULN) or clinical jaundice in the absence of cholestasis or other 
causes of hyperbilirubinemia is considered to be an indicator of severe liver injury (as 
defined by Hay's Law).  Therefore, investigators must report as an adverse event the 
occurrence of either of the following:

Treatment-emergent ALT or AST 3 ULN in combination with total bilirubin 
2ULN

Treatment-emergent ALT or AST 3 ULN in combination with clinical jaundice
The most appropriate diagnosis or (if a diagnosis cannot be established) the abnormal 
laboratory values should be recorded on the adverse event eCRF (see Section 5.3.5.6) 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event), either as a serious adverse event or an adverse event of special interest (see 
Section 5.4.2).
5.3.5.9
Deaths
All deaths that occur during the protocol-specified adverse event reporting period (see 
Section 5.3.1), regardless of relationship to study drug, must be recorded on the adverse 
event eCRF and immediately reported to the Sponsor (see Section 5.4.2).  This includes 
death attributed to progression of AD.
Death should be considered an outcome and not a distinct event.  The event or condition 
that caused or contributed to the fatal outcome should be recorded as the single medical 
concept on the adverse event eCRF.  Generally, only one such event should be reported.  
If the cause of death is unknown and cannot be ascertained at the time of reporting, 
"unexplained death" should be recorded on the adverse event eCRF.  If the cause of 
death later becomes available (e.g., after autopsy), "unexplained death" should be 
replaced by the established cause of death.  The term "sudden death" should not be 
used unless combined with the presumed cause of death (e.g., "sudden cardiac death").

Gantenerumab —F. Hoffmann-La Roche Ltd
57/Protocol WN41874, Version 2
If the death is attributed solely to progression of AD, "Alzheimer’s disease progression" 
should be recorded on the adverse event eCRF.
Deaths that occur after the adverse event reporting period should be reported as 
described in Section 5.6.
5.3.5.10
Preexisting Medical Conditions
A preexisting medical condition is one that is present at the Day 1 visit for this study.
Adverse events, resolved or ongoing, reported in the OLEs of Studies WN25203 and 
WN28745 should be considered as medical history in this study. Such conditions should 
be recorded on the General Medical History and Baseline Conditions eCRF.
A preexisting medical condition should be recorded as an adverse event only if the 
frequency, severity, or character of the condition worsens during the study.  When 
recording such events on the adverse event eCRF, it is important to convey the concept 
that the preexisting condition has changed by including applicable descriptors 
(e.g., "more frequent headaches").
5.3.5.11
Lack of Efficacy or Worsening of Alzheimer’s Disease
Events that are clearly consistent with the expected pattern of progression of the 
underlying disease should not be recorded as adverse event.  If there is any uncertainty 
as to whether an event is due to disease progression, it should be reported as an 
adverse event.
5.3.5.12
Hospitalization or Prolonged Hospitalization
Any adverse event that results in hospitalization (i.e., inpatient admission to a hospital) 
or prolonged hospitalization should be documented and reported as a serious adverse 
event (per the definition of serious adverse event in Section 5.2.2).
An event that leads to hospitalization under the following circumstances should not be 
reported as an adverse event or a serious adverse event:

Hospitalization for respite care

Planned hospitalization required by the protocol (e.g., for study drug administration
or insertion of access device for study drug administration)

Hospitalization for a preexisting condition, provided that all of the following criteria
are met:
–
The hospitalization was planned prior to the study or was scheduled during the
study when elective surgery became necessary because of the expected
normal progression of the disease
–
The participant has not experienced an adverse event

Gantenerumab —F. Hoffmann-La Roche Ltd
58/Protocol WN41874, Version 2
5.3.5.13
Cases of Accidental Overdose or Medication Error
Accidental overdose and medication error (hereafter collectively referred to as "special 
situations") are defined as follows:

Accidental overdose:  accidental administration of a drug in a quantity that is higher 
than the assigned dose

Medication error:  accidental deviation in the administration of a drug
In some cases, a medication error may be intercepted prior to administration of the drug.
Special situations are not in themselves adverse events, but may result in adverse 
events.  Each adverse event associated with a special situation should be recorded 
separately on the adverse event eCRF.  If the associated adverse event fulfills 
seriousness criteria or qualifies as an adverse event of special interest, the event should 
be reported to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event; see Section 5.4.2).  For gantenerumab, adverse events associated with special 
situations should be recorded as described below for each situation:

Accidental overdose:  Enter the adverse event term.  Check the "Accidental 
overdose" and "Medication error" boxes.

Medication error that does not qualify as an overdose:  Enter the adverse event term.  
Check the "Medication error" box.

Medication error that qualifies as an overdose:  Enter the adverse event term.  
Check the "Accidental overdose" and “Medication error” boxes.
In addition, all special situations associated with gantenerumab, regardless of whether 
they result in an adverse event, should be recorded on the adverse event eCRF as 
described below:

Accidental overdose:  Enter the drug name and "accidental overdose" as the event 
term.  Check the "Accidental overdose" and "Medication error" boxes

Medication error that does not qualify as an overdose:  Enter the name of the drug 
administered and a description of the error (e.g., wrong dose administered, wrong 
dosing schedule, incorrect route of administration, wrong drug, expired drug 
administered) as the event term.  Check the "Medication error" box

Medication error that qualifies as an overdose:  Enter the drug name and 
"Accidental overdose" as the event term.  Check the "Accidental overdose" and 
"Medication error" boxes.  Enter a description of the error in the additional case 
details

Intercepted medication error:  Enter the drug name and "intercepted medication 
error" as the event term.  Check the "Medication error" box.  Enter a description of 
the error in the additional case details.
As an example, an accidental overdose that resulted in a headache would require two 
entries on the adverse event eCRF, one entry to report the accidental overdose and one 

Gantenerumab —F. Hoffmann-La Roche Ltd
59/Protocol WN41874, Version 2
entry to report the headache.  The "Accidental overdose" and "Medication error" boxes 
would need to be checked for both entries.
5.4
IMMEDIATE REPORTING REQUIREMENTS FROM 
INVESTIGATOR TO SPONSOR
Certain events require immediate reporting to allow the Sponsor to take appropriate 
measures to address potential new risks in a clinical study.  The investigator must report 
such events to the Sponsor immediately; under no circumstances should reporting take 
place more than 24 hours after the investigator learns of the event.  The following is a list 
of events that the investigator must report to the Sponsor within 24 hours after learning 
of the event, regardless of relationship to study drug:

Serious adverse events (defined in Section 5.2.2; see Section 5.4.2 for details on 
reporting requirements)

Adverse events of special interest (defined in Section 5.2.3; see Section 5.4.2 for 
details on reporting requirements)

Pregnancies (see Section 5.4.3 for details on reporting requirements)

Medical device complaints (see Section 5.4.4 for details on reporting requirements)
For serious adverse events and adverse events of special interest, the investigator must 
report new significant follow-up information to the Sponsor immediately (i.e., no more 
than 24 hours after becoming aware of the information).  New significant information 
includes the following:

New signs or symptoms or a change in the diagnosis

Significant new diagnostic test results

Change in causality based on new information

Change in the event’s outcome, including recovery

Additional narrative information on the clinical course of the event
Investigators must also comply with local requirements for reporting serious adverse 
events to the local health authority and IRB/EC.
5.4.1
Emergency Medical Contacts
Medical Monitor Contact Information 
Medical Monitor:
, M.D. (Primary)
Mobile Telephone No.:
Medical Monitor:
 MBBS, MA (Cantab), 
Ph.D. (Secondary)
Mobile Telephone No.:
To ensure the safety of study participants, an Emergency Medical Call Center Help Desk 
will access the Roche Medical Emergency List, escalate emergency medical calls, 

Gantenerumab —F. Hoffmann-La Roche Ltd
60/Protocol WN41874, Version 2
provide medical translation service (if necessary), connect the investigator with a Roche 
Medical Responsible (listed above and/or on the Roche Medical Emergency List), and 
track all calls.  The Emergency Medical Call Center Help Desk will be available 24 hours 
per day, 7 days per week.  Toll-free numbers for the Help Desk, as well as Medical 
Monitor and Medical Responsible contact information, will be distributed to all 
investigators. 
5.4.2
Reporting Requirements for Serious Adverse Events and 
Adverse Events of Special Interest 
5.4.2.1
Events That Occur prior to Study Drug Initiation
After informed consent has been obtained but prior to initiation of study drug, only 
serious adverse events caused by a protocol-mandated intervention should be reported.
The paper Clinical Trial Adverse Event/Special Situations Form provided to 
investigators should be completed and submitted to the Sponsor or its designee 
immediately (i.e., no more than 24 hours after learning of the event), either by faxing or 
by scanning and emailing the form using the fax number or email address provided to 
investigators.
5.4.2.2
Events That Occur after Study Drug Initiation
After initiation of study drug, serious adverse events and adverse events of special 
interest will be reported until the participant’s last visit (including long-term follow-up 
visits).  Investigators should record all case details that can be gathered immediately (i.e., 
within 24 hours after learning of the event) on the adverse event eCRF and submit the 
report via the electronic data capture (EDC) system.  A report will be generated and sent 
to Roche Safety Risk Management by the EDC system.
In the event that the EDC system is unavailable, the paper Clinical Trial Adverse 
Event/Special Situations Form provided to investigators should be completed and 
submitted to the Sponsor or its designee immediately (i.e., no more than 24 hours after 
learning of the event), either by faxing or by scanning and emailing the form using the 
fax number or email address provided to investigators.  Once the EDC system is 
available, all information will need to be entered and submitted via the EDC system.  
Instructions for reporting serious adverse events that occur after the adverse event
reporting period are provided in Section 5.6.
5.4.3
Reporting Requirements for Pregnancies
5.4.3.1
Pregnancies in Female Participants
Female participants of childbearing potential will be instructed through the Informed 
Consent Form to immediately inform the investigator if they become pregnant during the 
study or within 16 weeks after the last dose of study drug.  A paper Clinical Trial 
Pregnancy Reporting Form should be completed and submitted to the Sponsor or its 
designee immediately (i.e., no more than 24 hours after learning of the pregnancy), 

Gantenerumab —F. Hoffmann-La Roche Ltd
61/Protocol WN41874, Version 2
either by faxing or by scanning and emailing the form using the fax number or email 
address provided to investigators.  Pregnancy should not be recorded on the adverse 
event eCRF.  The investigator should discontinue study drug and counsel the participant, 
discussing the risks of the pregnancy and the possible effects on the fetus.  Monitoring 
of the participant should continue until conclusion of the pregnancy.  Any serious 
adverse event associated with the pregnancy (e.g., an event in the fetus, an event in the 
mother during or after the pregnancy, or a congenital anomaly/birth defect in the child) 
should be reported on the adverse event eCRF.  In addition, the investigator will submit 
a Clinical Trial Pregnancy Reporting Form when updated information on the course and 
outcome of the pregnancy becomes available.  
5.4.3.2
Abortions
A spontaneous abortion should be classified as a serious adverse event (as the Sponsor 
considers abortions to be medically significant), recorded on the adverse event eCRF, 
and reported to the Sponsor immediately (i.e., no more than 24 hours after learning of 
the event; see Section 5.4.2).  
If a therapeutic or elective abortion was performed because of an underlying maternal or 
embryo-fetal toxicity, the toxicity should be classified as a serious adverse event, 
recorded on the adverse event eCRF, and reported to the Sponsor immediately (i.e., no 
more than 24 hours after learning of the event; see Section 5.4.2).  A therapeutic or 
elective abortion performed for reasons other than an underlying maternal or 
embryo-fetal toxicity is not considered an adverse event.
All abortions should be reported as pregnancy outcomes on the paper Clinical Trial 
Pregnancy Reporting Form. 
5.4.3.3
Congenital Anomalies/Birth Defects
Any congenital anomaly/birth defect in a child born to a female participant exposed to 
study drug should be classified as a serious adverse event, recorded on the adverse 
event eCRF, and reported to the Sponsor immediately (i.e., no more than 24 hours after 
learning of the event; see Section 5.4.2).
5.4.4
Reporting Requirements for Medical Device Complaints
The investigator must report all medical device complaints (e.g., devices for study drug 
administration) to the Sponsor.  The investigator should document as much information 
as possible on the IMP Deviation Form, including the product batch number, and forward 
the form to the Sponsor immediately (i.e., no more than 24 hours after learning of the 
event) (refer to the pharmacy manual for further details).  If the medical device results in 
an adverse event to the study participant, the event must be reported on the adverse 
event eCRF and submitted through the EDC system.  If the event is serious, the adverse 
event eCRF must be completed immediately (i.e., no more than 24 hours after learning 
of the event), as outlined in Section 5.4.2.

Gantenerumab —F. Hoffmann-La Roche Ltd
62/Protocol WN41874, Version 2
5.5
FOLLOW-UP OF PARTICIPANTS AFTER ADVERSE EVENTS
5.5.1
Investigator Follow-Up
The investigator should follow each adverse event until the event has resolved to baseline 
grade or better, the event is assessed as stable by the investigator, the participant is lost to 
follow-up, or the participant withdraws consent.  Every effort should be made to follow all 
serious adverse events considered to be related to study drug or study-related procedures 
until a final outcome can be reported.
During the study period, resolution of adverse events (with dates) should be documented 
on the adverse event eCRF and in the participant’s medical record to facilitate source data 
verification.
All pregnancies reported during the study should be followed until pregnancy outcome.
5.5.2
Sponsor Follow-Up
For serious adverse events, adverse events of special interest, and pregnancies, the 
Sponsor or a designee may follow up by telephone, fax, email, and/or a monitoring visit 
to obtain additional case details and outcome information (e.g., from hospital discharge 
summaries, consultant reports, autopsy reports) to perform an independent medical 
assessment of the reported case.
5.6
ADVERSE EVENTS THAT OCCUR AFTER THE ADVERSE 
EVENT REPORTING PERIOD
The Sponsor should be notified if the investigator becomes aware of any serious 
adverse event that occurs after the end of the adverse event reporting period (defined as 
the participant’s last study visit), if the event is believed to be related to prior study drug 
treatment.  These events should be reported through use of the adverse event eCRF.  
However, if the EDC system is not available, the investigator should report these events 
directly to the Sponsor or its designee, either by faxing or by scanning and emailing the 
paper Clinical Trial Adverse Event/Special Situations Form using the fax number or 
email address provided to investigators.
5.7
EXPEDITED REPORTING TO HEALTH AUTHORITIES, 
INVESTIGATORS, INSTITUTIONAL REVIEW BOARDS, AND 
ETHICS COMMITTEES
The Sponsor will promptly evaluate all serious adverse events and adverse events of 
special interest against cumulative product experience to identify and expeditiously 
communicate possible new safety findings to investigators, IRBs, ECs, and applicable 
health authorities based on applicable legislation.

Gantenerumab —F. Hoffmann-La Roche Ltd
63/Protocol WN41874, Version 2
To determine reporting requirements for single adverse event cases, the Sponsor will 
assess the expectedness of these events through use of the reference safety 
information in the document listed below:  
Drug
Document
Gantenerumab
Gantenerumab Investigator's Brochure
The Sponsor will compare the severity of each event and the cumulative event 
frequency reported for the study with the severity and frequency reported in the 
applicable reference document.
Reporting requirements will also be based on the investigator's assessment of causality 
and seriousness, with allowance for upgrading by the Sponsor as needed.
6.
STATISTICAL CONSIDERATIONS AND ANALYSIS PLAN
6.1
DETERMINATION OF SAMPLE SIZE
The purpose of this study is to assess the long-term safety and tolerability of 
gantenerumab in participants who complete the OLEs of Studies WN25203 or WN28745. 
The sample size will include all eligible participants who consent to this study.
Therefore, in Part 1 of the study, the sample size was driven by the number of 
participants who complete the OLE part of Studies WN25203 or WN28745 and 
subsequently enrolled in this study. There were 116 participants that participated in 
Part 1 of the study. 
For Part 2, the sample size is expected to be no more than 116 participants.
6.2
SUMMARIES OF CONDUCT OF STUDY
Participant disposition (including withdrawals from treatment) and protocol deviations will 
be summarized descriptively for all participants in the safety population who receive at 
least one dose of treatment in this study.
6.3
SUMMARIES OF DEMOGRAPHIC AND BASELINE 
CHARACTERISTICS
Demographic and baseline characteristics (such as age, sex, race, disease stage, and
APOE 4 status) will be summarized descriptively for all participants enrolled in the 
safety population.
Descriptive summaries of continuous data will present the mean, SD, median, and 
minimum and maximum. Descriptive summaries of discrete data will include frequencies 
expressed in terms of the number and percentage of participants.

Gantenerumab —F. Hoffmann-La Roche Ltd
64/Protocol WN41874, Version 2
6.4
EFFICACY ANALYSES
There will be no formal confirmatory efficacy analyses for this study.
6.4.1
Exploratory Efficacy Endpoints
To monitor AD progression, MMSE will be summarized using mean, SD, median, 
inter-quartile range and minimum and maximum. No hypothesis testing will be 
performed.
6.4.2
Secondary Efficacy Endpoints
Not applicable.
6.5
SAFETY ANALYSES
The safety analysis population will include all participants in the safety population who 
received at least one dose of study drug.  The following safety outcome measures will be 
summarized using descriptive statistics:

Incidence, nature, severity, and timing of adverse events

Incidence, nature, severity, and timing of serious adverse events

Changes from baseline of this study in vital signs, blood tests, ECGs, and C-SSRS

Incidence, nature, severity, and timing of MRI safety findings:  ARIA-E and ARIA-H

Incidence, nature, severity, and timing of ISRs

Number and proportion of ADA-positive and ADA-negative participants during both 
the treatment and follow-up periods

Incidence of treatment discontinuations for adverse events

Incidence of adverse events of special interest 
Statistical methods, endpoint definitions and analyses of the safety endpoints will be 
described in the Statistical Analysis Plan.  
6.6
PHARMACOKINETIC ANALYSES 
No dedicated pharmacokinetic (PK) analysis will be performed for this study.
Gantenerumab plasma concentration results obtained for ADA assessment may be 
pooled with results from other studies for the population PK analysis.
6.7
BIOMARKER ANALYSES
Exploratory biomarker analyses will include MRI volumetric changes.
6.8
INTERIM ANALYSIS
No interim analyses will be planned for this study.

Gantenerumab —F. Hoffmann-La Roche Ltd
65/Protocol WN41874, Version 2
7.
DATA COLLECTION AND MANAGEMENT
7.1
DATA QUALITY ASSURANCE
The Sponsor will be responsible for data management of this study, including quality 
checking of the data.  Data entered manually will be collected via EDC through use of 
eCRFs.  Sites will be responsible for data entry into the EDC system.  In the event of 
discrepant data, the Sponsor will request data clarification from the sites, which the sites 
will resolve electronically in the EDC system.
The Sponsor will produce an EDC Study Specification document that describes the 
quality checking to be performed on the data.  All electronic data from external vendors 
will be sent directly to the Sponsor, using the Sponsor’s standard procedures to handle 
and process the electronic transfer of these data.
Electronic Case Report Forms and correction documentation will be maintained in the 
EDC system’s audit trail.  System backups for data stored by the Sponsor and records 
retention for the study data will be consistent with the Sponsor’s standard procedures.
7.2
ELECTRONIC CASE REPORT FORMS 
Electronic Case Report Forms are to be completed through use of a Sponsor-designated 
EDC system.  Sites will receive training and have access to a manual for appropriate 
eCRF completion.  Electronic Case Report Forms will be submitted electronically to the 
Sponsor and should be handled in accordance with instructions from the Sponsor.
All eCRFs should be completed by designated, trained site staff.  Electronic Case Report 
Forms should be reviewed and electronically signed and dated by the investigator or a 
designee.
At the end of the study, the investigator will receive participant data for his or her site in a 
readable format on a compact disc that must be kept with the study records.  
Acknowledgment of receipt of the compact disc is required.
7.3
ELECTRONIC DATA 
Once the study is complete, the data, audit trail, and study and system documentation 
will be archived.  The investigator will receive participant data for the site in both human-
and machine-readable formats on an archival-quality compact disc that must be kept 
with the study records as source data.  Acknowledgment of receipt of the compact disc 
is required.  In addition, the Sponsor will receive all data in a machine-readable format 
on a compact disc.
7.4
SOURCE DATA DOCUMENTATION
Study monitors will perform ongoing source data verification to confirm that critical 
protocol data (i.e., source data) entered into the eCRFs by authorized site personnel are 
accurate, complete, and verifiable from source documents. 

Gantenerumab —F. Hoffmann-La Roche Ltd
66/Protocol WN41874, Version 2
Source documents (paper or electronic) are those in which participant data are recorded 
and documented for the first time.  They include, but are not limited to, hospital records, 
clinical and office charts, laboratory notes, memoranda, participant-reported outcomes, 
evaluation checklists, pharmacy dispensing records, recorded data from automated 
instruments, copies of transcriptions that are certified after verification as being accurate 
and complete, microfiche, photographic negatives, microfilm or magnetic media, X-rays, 
participant files, and records kept at pharmacies, laboratories, and medico-technical 
departments involved in a clinical study.
Before study initiation, the types of source documents that are to be generated will be 
clearly defined in the Trial Monitoring Plan.  This includes any protocol data to be 
entered directly into the eCRFs (i.e., no prior written or electronic record of the data) and 
considered source data.
Source documents that are required to verify the validity and completeness of data 
entered into the eCRFs must not be obliterated or destroyed and must be retained per 
the policy for retention of records described in Section 7.6.
To facilitate source data verification, the investigators and institutions must provide the 
Sponsor direct access to applicable source documents and reports for 
study-related-monitoring, Sponsor audits, and IRB/EC review.  The study site must also 
allow inspection by applicable health authorities.
7.5
USE OF COMPUTERIZED SYSTEMS
When clinical observations are entered directly into a study site’s computerized medical 
record system (i.e., in lieu of original hardcopy records), the electronic record can serve 
as the source document if the system has been validated in accordance with health 
authority requirements pertaining to computerized systems used in clinical research.  An 
acceptable computerized data collection system allows preservation of the original entry 
of data.  If original data are modified, the system should maintain a viewable audit trail 
that shows the original data as well as the reason for the change, name of the person 
making the change, and date of the change.
7.6
RETENTION OF RECORDS
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, including eCRFs, ICFs, laboratory test results, and medication inventory records, 
must be retained by the Principal Investigator for at least 15 years after completion or 
discontinuation of the study or for the length of time required by relevant national or local 
health authorities, whichever is longer.  After that period of time, the documents may be
destroyed, subject to local regulations.  
No records may be disposed of without the written approval of the Sponsor.  Written 
notification should be provided to the Sponsor prior to transferring any records to 
another party or moving them to another location.

Gantenerumab —F. Hoffmann-La Roche Ltd
67/Protocol WN41874, Version 2
Roche will retain study data for 25 years after the final study results have been reported 
or for the length of time required by relevant national or local health authorities, 
whichever is longer.
8.
ETHICAL CONSIDERATIONS
8.1
COMPLIANCE WITH LAWS AND REGULATIONS
This study will be conducted in full conformance with the ICH E6 guideline for GCP and 
the principles of the Declaration of Helsinki, or the laws and regulations of the country in 
which the research is conducted, whichever affords the greater protection to the 
individual.  The study will comply with the requirements of the ICH E2A guideline 
(Clinical Safety Data Management:  Definitions and Standards for Expedited Reporting).  
Studies conducted in the United States or under a U.S. Investigational New Drug (IND) 
Application will comply with U.S. Food and Drug Administration regulations and 
applicable local, state, and federal laws.  Studies conducted in the European Union or 
European Economic Area will comply with the E.U. Clinical Trial Directive (2001/20/EC).
8.2
INFORMED CONSENT
The Sponsor’s sample ICF (and ancillary sample ICFs such as HN ICF, if applicable) will 
be provided to each site.  If applicable, it will be provided in a certified translation of the 
local language.  The Sponsor or its designee must review and approve any proposed 
deviations from the Sponsor's sample ICFs or any alternate Consent Forms proposed by 
the site (collectively, the "Consent Forms") before IRB/EC submission.  The final 
IRB/EC-approved Consent Forms must be provided to the Sponsor for health authority 
submission purposes according to local requirements.
If applicable, the ICF will contain separate sections for any optional procedures.  The 
investigator or authorized designee will explain to each participant the objectives, 
methods, and potential risks associated with each optional procedure.  Participants will 
be told that they are free to refuse to participate and may withdraw their consent at any 
time for any reason.  A separate, specific signature will be required to document a 
participant's agreement to participate in optional procedures.  Participants who decline to 
participate will not provide a separate signature.
The Consent Forms must be signed and dated by the participant or the participant’s LAR 
before his or her participation in the study.  The case history or clinical records for each 
participant shall document the informed consent process and that written informed 
consent was obtained prior to participation in the study.
The Consent Forms should be revised whenever there are changes to study procedures 
or when new information becomes available that may affect the willingness of the 
participant to participate in the study.  The final revised IRB/EC-approved Consent 
Forms must be provided to the Sponsor for health authority submission purposes.

Gantenerumab —F. Hoffmann-La Roche Ltd
68/Protocol WN41874, Version 2
If the Consent Forms are revised (through an amendment or an addendum) while a 
participant is participating in the study, the participant or a LAR must re-consent by 
signing the most current version of the Consent Forms or the addendum, in accordance 
with applicable laws and IRB/EC policy.  For any updated or revised Consent Forms, the 
case history or clinical records for each participant shall document the informed consent 
process and that written informed consent was obtained using the updated/revised 
Consent Forms for continued participation in the study.
A copy of each signed Consent Form must be provided to the participant or the 
participant’s LAR.  All signed and dated Consent Forms must remain in each 
participant’s study file or in the site file and must be available for verification by study 
monitors at any time.
For sites in the United States, each Consent Form may also include participant
authorization to allow use and disclosure of personal health information in compliance 
with the U.S. Health Insurance Portability and Accountability Act (HIPAA) of 1996.  If the 
site utilizes a separate Authorization Form for participant authorization for use and 
disclosure of personal health information under the HIPAA regulations, the review, 
approval, and other processes outlined above apply except that IRB review and approval 
may not be required per study site policies.
8.3
INSTITUTIONAL REVIEW BOARD OR ETHICS COMMITTEE
This protocol, the ICFs, any information to be given to the participant, and relevant 
supporting information must be submitted to the IRB/EC by the Principal Investigator and 
reviewed and approved by the IRB/EC before the study is initiated.  In addition, any 
participant recruitment materials must be approved by the IRB/EC. 
The Principal Investigator is responsible for providing written summaries of the status of 
the study to the IRB/EC annually or more frequently in accordance with the requirements, 
policies, and procedures established by the IRB/EC.  Investigators are also responsible 
for promptly informing the IRB/EC of any protocol amendments (see Section 9.7).
In addition to the requirements for reporting all adverse events to the Sponsor, 
investigators must comply with requirements for reporting serious adverse events to the 
local health authority and IRB/EC.  Investigators may receive written IND safety reports 
or other safety-related- communications from the Sponsor.  Investigators are responsible 
for ensuring that such reports are reviewed and processed in accordance with health 
authority requirements and the policies and procedures established by their IRB/EC, and 
archived in the site’s study file. 
8.4
CONFIDENTIALITY
The Sponsor maintains confidentiality standards by coding each participant enrolled in 
the study through assignment of a unique participant identification number.  This means 

Gantenerumab —F. Hoffmann-La Roche Ltd
69/Protocol WN41874, Version 2
that participant names are not included in data sets that are transmitted to any Sponsor 
location.
Participant medical information obtained by this study is confidential and may be 
disclosed to third parties only as permitted by the ICF (or separate authorization for use 
and disclosure of personal health information) signed by the participant, unless permitted 
or required by law.
Medical information may be given to a participant’s personal physician or other 
appropriate medical personnel responsible for the participant’s welfare, for treatment 
purposes.
Given the complexity and exploratory nature of exploratory biomarker analyses, data 
derived from these analyses will generally not be provided to study investigators or 
participants unless required by law (with the exception of the report from Foundation 
Medicine). The aggregate results of any conducted research will be available in 
accordance with the effective Sponsor policy on study data publication (see Section 9.6).
Data generated by this study must be available for inspection upon request by 
representatives of national and local health authorities, Sponsor monitors, 
representatives, and collaborators, and the IRB/EC for each study site, as appropriate.
Study data may be submitted to government or other health research databases or 
shared with researchers, government agencies, companies, or other groups that are not 
participating in this study.  These data may be combined with or linked to other data and 
used for research purposes, to advance science and public health, or for analysis, 
development, and commercialization of products to treat and diagnose disease. In 
addition, redacted Clinical Study Reports and other summary reports will be provided 
upon request (see Section 9.6).
8.5
FINANCIAL DISCLOSURE
Investigators will provide the Sponsor with sufficient, accurate financial information in 
accordance with local regulations to allow the Sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate health authorities.  
Investigators are responsible for providing information on financial interests during the 
course of the study and for one year after completion of the study (see definition of end 
of study in Section 3.2).
9.
STUDY DOCUMENTATION, MONITORING, AND 
ADMINISTRATION
9.1
STUDY DOCUMENTATION
The investigator must maintain adequate and accurate records to enable the conduct of 
the study to be fully documented, including, but not limited to, the protocol, protocol 

Gantenerumab —F. Hoffmann-La Roche Ltd
70/Protocol WN41874, Version 2
amendments, ICFs, and documentation of IRB/EC and governmental approval.  In 
addition, at the end of the study, the investigator will receive the participant data, 
including an audit trail containing a complete record of all changes to data.
9.2
PROTOCOL DEVIATIONS
The investigator should document and explain any protocol deviations.  The investigator 
should promptly report any deviations that might have an impact on participant safety 
and data integrity to the Sponsor and to the IRB/EC in accordance with established 
IRB/EC policies and procedures.  The Sponsor will review all protocol deviations and 
assess whether any represent a serious breach of GCP guidelines and require reporting 
to health authorities.  As per the Sponsor's standard operating procedures, prospective 
requests to deviate from the protocol, including requests to waive protocol eligibility 
criteria, are not allowed.
9.3
MANAGEMENT OF STUDY QUALITY
The Sponsor will implement a system to manage the quality of the study, focusing on 
processes and data that are essential to ensuring participant safety and data integrity.  
Prior to study initiation, the Sponsor will identify potential risks associated with critical 
study processes and data and will implement plans for evaluating and controlling these 
risks. Risk evaluation and control will include the selection of risk-based parameters 
(e.g., adverse event rate, protocol deviation rate) and the establishment of quality 
tolerance limits for these parameters prior to study initiation. Detection of deviations 
from quality tolerance limits will trigger an evaluation to determine if action is needed. 
Details on the establishment and monitoring of quality tolerance limits will be provided in 
a Quality Tolerance Limit Management Plan.
9.4
SITE INSPECTIONS
Site visits will be conducted by the Sponsor or an authorized representative for 
inspection of study data, participants’ medical records, and eCRFs.  The investigator will 
permit national and local health authorities; Sponsor monitors, representatives, and 
collaborators; and the IRBs/ECs to inspect facilities and records relevant to this study.
9.5
ADMINISTRATIVE STRUCTURE
The overall procedures for quality assurance of clinical study data are described in the 
Roche standard operating procedures.  This study will be sponsored by 
F. Hoffmann-La Roche Ltd. Roche will provide clinical operations oversight, site 
monitoring and management, data management support, and medical monitoring. 
Approximately 60 sites globally have participated to enroll up to 116 participants in 
Part 1 of the study. Enrollment has taken place through an IxRS. Study drug distribution 
may occur through an IxRS (see Section 4.2).  Central facilities may be used for study 
assessments (i.e., ECG, lumbar puncture, specified laboratory tests, pharmacokinetics, 
rating scales, and MRI and PET imaging, as applicable).

Gantenerumab —F. Hoffmann-La Roche Ltd
71/Protocol WN41874, Version 2
9.6
DISSEMINATION OF DATA AND PROTECTION OF 
TRADE SECRETS
Regardless of the outcome of a study, the Sponsor is dedicated to openly providing 
information on the study to healthcare professionals and to the public, both at scientific 
congresses and in peer-reviewed journals. The Sponsor will comply with all 
requirements for publication of study results.  Study data may be shared with others who 
are not participating in this study (see Section 8.4 for details), and redacted Clinical 
Study Reports and other summary reports will be made available upon request. For 
more information, refer to the Roche Global Policy on Sharing of Clinical Study 
Information at the following website:
www.roche.com/roche_global_policy_on_sharing_of_clinical_study_information.pdf
The results of this study may be published or presented at scientific congresses.  For all 
clinical studies in participants involving an IMP for which a marketing authorization 
application has been filed or approved in any country, the Sponsor aims to submit a 
journal manuscript reporting primary clinical study results within six months after the 
availability of the respective Clinical Study Report.  In addition, for all clinical studies in 
participants involving an IMP for which a marketing authorization application has been 
filed or approved in any country, the Sponsor aims to publish results from analyses of 
additional endpoints and exploratory data that are clinically meaningful and statistically 
sound.
The investigator must agree to submit all manuscripts or abstracts to the Sponsor prior 
to submission for publication or presentation.  This allows the Sponsor to protect 
proprietary information and to provide comments based on information from other 
studies that may not yet be available to the investigator.
In accordance with standard editorial and ethical practice, the Sponsor will generally 
support publication of multicenter studies only in their entirety and not as individual
center data.  In this case, a coordinating investigator will be designated by mutual 
agreement.
Authorship will be determined by mutual agreement and in line with International 
Committee of Medical Journal Editors authorship requirements.  Any formal publication 
of the study in which contribution of Sponsor personnel exceeded that of conventional 
monitoring will be considered as a joint publication by the investigator and the 
appropriate Sponsor personnel.
Any inventions and resulting patents, improvements, and/or know-how originating from 
the use of data from this study will become and remain the exclusive and unburdened 
property of the Sponsor, except where agreed otherwise.

Gantenerumab —F. Hoffmann-La Roche Ltd
72/Protocol WN41874, Version 2
9.7
PROTOCOL AMENDMENTS
Any protocol amendments will be prepared by the Sponsor.  Protocol amendments will 
be submitted to the IRB/EC and to regulatory authorities in accordance with local 
regulatory requirements.
Approval must be obtained from the IRB/EC and regulatory authorities (as locally 
required) before implementation of any changes, except for changes necessary to 
eliminate an immediate hazard to participants or changes that involve logistical or 
administrative aspects only (e.g., change in Medical Monitor or contact information).

Gantenerumab —F. Hoffmann-La Roche Ltd
73/Protocol WN41874, Version 2
10.
REFERENCES
Bateman RJ, Benzinger TL, Berry S, et al. The DIAN-TU Next Generation Alzheimer’s 
prevention trial: adaptive design and disease progression model. Alzheimer’s 
Dementia 2017;13:819.
Brookmeyer R, Corrada MM, Curriero, et al. Survival following a diagnosis of 
Alzheimer’s disease. Arch Neurology 2002;59:17647. 
Citron M. Strategies for disease modification in Alzheimer’s disease. Nature 
Reviews/Neuroscience 2004; 5:677685.
Cummings JL. Alzheimers disease. N Engl J Med 2004;351:5667.
Cummings JL, Aisen PS, DuBois B, et al. Drug development in Alzheimer’s disease: the 
path to 2025. Alzheimers Res Ther 2016;8:39.
Fox NC, Black RS, Gilman S, et al. Effects of Aimmunization (AN1792) on MRI 
measures of cerebral volume in Alzheimer disease. Neurology 2005;64:156372.
Fox NC, Cousens S, Scahill R, et al. Using serial registered brain magnetic resonance 
imaging to measure disease progression in Alzheimer disease: power calculations 
and estimates of sample size to detect treatment effects. Arch Neurol 2000;57:
33944.
Fox NC, Kennedy J. Structural imaging markers for therapeutic trials in Alzheimer’s 
disease. J Nutr Health Aging 2009;13:3502.
Gantenerumab Investigator's Brochure, version 15, July 2019.
Helzner EP, Scarmeas N, Cosentino S, et al. Survival in Alzheimer’s disease: 
a multiethnic, population-based study of incident cases. Neurology 
2008;71:148995. 
Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers 
of the Alzheimer’s pathological cascade. Lancet Neurol 2010;9:11928.
Klein G, Delmar P, Hofmann C, et al. Higher dose Gantenerumab leads to Significant 
Reduction in Amyloid Plaque Burden - Results for the Marguerite and Scarlet Road 
Open Label Extension Studies. J Prev Alzheimer’s Disease 2017;4:310.
Li TQ, Wahlund LO. The search for neuroimaging biomarkers of Alzheimer's diseasewith 
advanced MRI techniques. Acta Radiol 2011;52:21122.
Mungas D, Reed BR, Tomaszewski-Farias S, et al. Criterion-referenced validity of a 
neuropsychological test battery: equivalent performance in elderly Hispanics and 
non-Hispanic Whites. J Intl Neuropsychol Soc 2005;11:620–30.
Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients 
with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198207.

Gantenerumab —F. Hoffmann-La Roche Ltd
74/Protocol WN41874, Version 2
Ostrowitzki S, Lasser RA, Dorflinger E, et al. A phase III randomized trial of 
gantenerumab in prodromal Alzheimer's disease. Alzheimers Res Ther 2017;9:95.
Mesterton J, Wimo A, By A, et al. Cross sectional observational study on the societal 
costs of Alzheimer's disease.Curr Alzheimer Res. 2010; 7:358367.
Piazza F, Winblad B. Amyloid-related imaging abnormalities (ARIA) in immunotherapy 
trials for Alzheimer's disease: need for prognostic biomarkers? J Alzheimers Dis 
2016;52:41720.
Salloway S, Sperling R, Gilman S, et al., on behalf of the Bapineuzumab 201 clinical trial 
investigators. A phase 2 multiple ascending dose trial of bapineuzumab in mild to 
moderate Alzheimer’s disease. Neurology 2009;73:206170.
Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO 
Mol Med 2016;8:595608.
Sevigny JJ, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Aplaques 
in Alzheimer's disease. Nature 2016;537:506. 
Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in 
patients with Alzheimer’s disease treated with bapineuzumab: a retrospective 
analysis. Lancet Neurol 2012;11:2419.
Sun X, Chen WD, Wang YD. -Amyloid: the key peptide in the pathogenesis of 
Alzheimer's disease. Front Pharmacol 2015;6:221.
Swanson CJ, Zhang Y, Dhadda S, et al. Treatment of early AD subjects with BAN2401, 
an anti-Aβ protofibril monoclonal antibody, significantly clears amyloid plaque and 
reuces clinical decline. Alzheimer's & Dementia: The Journal of the Alzheimer's
Association 2018;14(7):P1668. DOI: https://doi.org/10.1016/j.jalz.2018.07.009.
Viglietta V, O’Gorman J, Williams L, et al. Aducanumab 24-month data from PRIME: 
a randomized, double-blind, placebo-controlled phase 1b study in patients with 
prodromal or mild Alzheimer’s disease. Presented at the Clinical Trials in 
Alzheimer’s Disease, San Diego, CA, 9 December 2016.
Wisniewski T, Goñi F. Immunotherapy for Alzheimer's disease. Biochem Pharmacol 
2014;88:499507.
World Health Organization. Dementia fact sheet [resource on the Internet]. December 
2017 [cited: 15 January 2018]. Available from:
http://www.who.int/mediacentre/factsheets/fs362/en/.

Gantenerumab —F. Hoffmann-La Roche Ltd
75/Protocol WN41874, Version 2
Appendix 1 Schedule of Activities (Part 1)
Weeks (7 days)
Day 1a
Treatment Period
Follow-Up/Early
Termination
UV k
W4-20
W24
W248-48
W52
W56-72
W76
W80100
W104
Informed consent(s) b
x b
Study Drug 
Administration
x
x
x
x
x
x
x
x
x
MRI c
x d
x
x d
x
x d
x l
x
Vital signs e
x
x
x
x
x
x
x
x
x
x
x
ECG f
x
x
Serum chemistry, 
,hematology g
x
x
x
x
x
Coagulation 
(prothrombin time) g
x
x
x
x
x
PK plasma sample h
x
x
x
x
Biomarker plasma 
sample h
x
x
x
x
ADA plasma sample h
x
x
x
x
Urine pregnancy test i
x
x
x
x
x
x
x
x
x
x
x
Adverse events
x
x
x
x
x
x
x
x
x
x
x
Concomitant meds
x
x
x
x
x
x
x
x
x
x
x
MMSE
x
x
x
x
x
x
x
C-SSRS j
x
x
x
x
x
x
x
Physical examination
x
x
x
x
x

Gantenerumab —F. Hoffmann-La Roche Ltd
76/Protocol WN41874, Version 2
Appendix 1 Schedule of Activities (Part 2)
Weeks (± 7 days)
W104
Treatment Period
Follow-
Up/Early 
Termination UV k
W108124 W128 W132152 W156
W160176
W180
W184204
W208
Informed consent(s) b
x b
Study Drug 
Administration
x
x
x
x
x
x
x
x
x
MRI c
x d
x
x d
x
x d
x l
x
Vital signs e
x
x
x
x
x
x
x
x
x
x
x
ECG f
x
Serum chemistry, , and 
hematology g
x
x
x
x
x
Coagulation 
(prothrombin time)
x
x
x
x
x
PK plasma sample h
x
x
x
x
Biomarker plasma
sample h
x
x
x
x
ADA plasma sample h
x
x
x
x
Urine pregnancy test i
x
x
x
x
x
x
x
x
x
x
x
Adverse events
x
x
x
x
x
x
x
x
x
x
x
Concomitant meds
x
x
x
x
x
x
x
x
x
x
x
MMSE
x
x
x
x
x
x
x
C-SSRS j
x
x
x
x
x
x
x
Physical examination
x
x
x
x
x

Gantenerumab —F. Hoffmann-La Roche Ltd
77/Protocol WN41874, Version 2
Appendix 1 Schedule of Activities (Part 1 and Part 2)
ADAanti-drug antibody; ALT/SGPT alanine aminotransferase/serum glutamicpyruvic transaminase; ARIAamyloid-related imaging 
abnormality; ARIA-Eamyloid-related imaging abnormality-edema/effusion; ARIA-Hamyloid-related imaging abnormality–hemosiderin 
deposition; AST/SGOT aspartate aminotransferase/serum glutamicoxaloacetic transaminase; BPblood pressure; BUNblood urea nitrogen; 
C-SSRSColumbia-Suicide Severity Rating Scale; ECG electrocardiogram; F1follow-up 1; HRheart rate; ICFInformed Consent Form; 
IMPinvestigational medicinal product; MMSEMini Mental State Examination; MRImagnetic resonance imaging; PIPrincipal Investigator; 
PKpharmacokinetic; Q4W every 4 weeks; UVUnscheduled Visit; WBCwhite blood cell.
Notes:  There is a7 day window for all visits.  However, the minimal time between doses is 21 days, and the target day for each Q4W visit is 
timed with respect to baseline, not to the prior visit.
Participants who will undergo an up-titration step, due to a dose gap of more than 16 weeks (see Appendix 3), will follow the same Schedule of 
Activities, except that an additional MRI will be performed before up-titration (further details in Appendix 3). Also, participants who have their 
dosing modified due to an ARIA-E event will follow the same Schedule of Activities, with the exception of any additional safety MRI scans that 
might be required (see Appendix 2).
a Day 1 visit is the baseline visit and the visit of the first IMP administration for this study. Day 1 visit should take place on the same day as the 
follow-up visit (4 weeks after last dose) of the qualifying studies whenever possible. 
The Day 1 vital signs, serum chemistry and hematology, urine pregnancy test, and physical examination results will be the same as in the 
post-treatment follow-up visit in Studies WN25203 and WN28745 if they occur on the same day or within 4 weeks.
The Day 1 MRI, MMSE, and C-SSRS will be the same as in the post-treatment follow-up visit in Studies WN25203 and WN28745 if they occur 
on the same day or within 6 months.
b Informed consent should be obtained by the participants before any study procedures are performed, and may be obtained while they are 
active in the qualifying study; however, enrollment in this study is contingent upon completion of the qualifying study, and any premature 
discontinuation of study participation or study drug in the qualifying study, or failure to meet any other eligibility criterion (see Section 4.1.1),
precludes enrollment in this study.
c MRI results should be available before dosing on Day 1.  At subsequent visits indicated in the schedule, MRI scans must be performed within 
20 days after dose administration and results made available and reviewed before the next scheduled dose.  Participants will be asked if they 
experience CNS adverse events up to one week before each MRI is performed.
d Includes volumetric outcome measures.
e Vital signs include HR, BP, and temperature.  The same arm should be used for all blood pressure measurements.  HR and BP should not be 
measured unless 15 minutes have passed since the last blood draw.  Weight will be recorded yearly at the time of physical examination.
f
Perform after the participant has been in a supine position for 5 minutes.  ECGs for each participant should be obtained at baseline and any 
time during the study if deemed necessary by the investigator from the same machine whenever possible and performed prior to any blood 
draws, brain MRI scans.

Gantenerumab —F. Hoffmann-La Roche Ltd
78/Protocol WN41874, Version 2
Appendix 1 Schedule of Activities (Part 1 and Part 2)
g Serum chemistry includes AST/SGOT, ALT/SGPT, alkaline phosphatase, total protein, total bilirubin, serum albumin, CPK, sodium, potassium, 
calcium, BUN, and serum creatinine (and creatinine clearance calculated by the central laboratory).  
Hematology includes hemoglobin, hematocrit, red blood cell (with morphology), WBCs, platelet, basophil, eosinophil, lymphocyte, monocyte, 
neutrophil, and WBC–other total counts.
h At all visits where biomarker plasma, PK, and ADA samples are needed, the samples should be obtained before administration of 
gantenerumab if applicable.  Accurate recording of the time of study drug administration and PK sampling is critical.
i
Female participants of childbearing potential (including those who have had a tubal ligation) must have a urine pregnancy test performed at 
the site prior to each dose administration.  If a urine pregnancy test is positive, it must be confirmed by a serum pregnancy test at the central 
laboratory.
j
C-SSRS (since last visit) should be obtained every 6 months and additionally at any time deemed necessary by the investigator.
k Only the relevant assessments will be performed, determined per the investigator’s clinical judgment, and do not necessarily include all those 
listed above.
l: MRI must be performed within 20 days after dose administration and results made available and reviewed before the final follow-up or 
drop-out visit to allow review before the final visit.  Participants will be asked if they experience CNS adverse events up to one week before 
each MRI is performed.

Gantenerumab —F. Hoffmann-La Roche Ltd
79/Protocol WN41874, Version 2
Appendix 2 Management Rules for Amyloid-Related Imaging Abnormalities
Event
Characteristics
Action to be Taken
ARIA-E
Asymptomatic ARIA-E 1 
and 4 BGTS 
Participants who had MRI on target dose:

Continue study drug at the same dose level and perform MRI scans at 4-week intervals until ARIA-E resolves, 
then resume the standard MRI schedule (Appendix 1)
Participants who had MRI prior to up-titration to target dose:

Continue study drug and do not up-titrate. Repeat MRI scan 4 weeks later

As long as BGTS is 4 and 1, continue study drug at the same dose level and continue MRI monitoring at 
4-week interval

Once ARIA-E resolves, complete up-titration to target dose and resume the standard MRI schedule (Appendix 1)
Symptomatic ARIA-E (of 
any size) or 
asymptomatic ARIA-E and 
BGTS 4
Participants who had MRI on target dose:

Temporarily interrupt study drug and perform MRI scans at 4-week intervals until symptoms and ARIA-E resolve

When symptoms and ARIA-E resolve, reintroduce study drug at target dose and resume the standard MRI 
schedule (Appendix 1)
Participants who had MRI prior to up-titration to target dose:

Temporarily interrupt study drug and perform MRI scans at 4-week intervals until symptoms and ARIA-E resolve

When symptoms and ARIA-E resolve, reintroduce study drug at the dose level given at the time the event was 
detected

After one dose at the dose level given at the time the event was detected, but before the next scheduled dose, 
perform a subsequent MRI scan

If no new ARIA-E is detected, then complete up-titration to target dose and resume the standard MRI schedule 
(Appendix 1)
Any recurrence of ARIA-E

Treat as above (based on symptoms and BGTS)
ARIA-H
Any disseminated LH 
(more than 3 focal LH)
Permanently discontinue study drug
Note: In the absence of disseminated LH, study drug can be continued, including up-titration to target dose

Gantenerumab —F. Hoffmann-La Roche Ltd
80/Protocol WN41874, Version 2
Appendix 2 Management Rules for Amyloid-Related Imaging Abnormalities (continued)
ARIA-Eamyloid-related imaging abnormalityedema/effusion; ARIA-Hamyloid-related imaging abnormalityhemosiderin deposition; 
BGTSBarkhof grand total score; CNScentral nervous system; LHleptomeningeal hemosiderosis; MRImagnetic resonance imaging; Q4W every 
4 weeks.
Notes:

Symptomatic ARIA-E is defined as onset or worsening of CNS symptom(s) that is/are temporally associated with ARIA-E MRI findings.

In exceptional cases of (1) an ARIA-E that is asymptomatic with BGTS <4 and considered stable over consecutive MRI images by the Sponsor and
investigator; or (2) symptomatic ARIA-E for which the imaging evidence of ARIA-E has resolved but the CNS symptoms continue, gantenerumab can
be either reintroduced or up-titrated, as applicable, and Q4W MRI monitoring may no longer be necessary, as determined by the Sponsor and
investigator.

Investigators may choose to perform additional MRI monitoring for ARIA at any time.

In this study, "up-titration to target dose" applies to participants who may have started with lower dose level due to the length of dosing gap and their
ARIA-E history (see Appendix 3) and need to return to the dose that they were receiving in the qualifying study (e.g., 1200 mg or 900 mg Q4W).